GLOBAL MAP DATA DICTIONARY #165.5 -- ONCOLOGY PRIMARY FILE 3/24/25 PAGE 1
STORED IN ^ONCO(165.5, *** NO DATA STORED YET *** SITE: WWW.BMIRWIN.COM UCI: VISTA,VISTA (VERSION 2.2)
-----------------------------------------------------------------------------------------------------------------------------------
Tumor-related data for Oncology patients is stored in this file. (Demographic and follow-up data is in the Oncology Patient File).
File is populated in the field by using the abstracting options.
CROSS
REFERENCED BY: ACCESSION NUMBER(AA), DATE CASE COMPLETED(AAD), DATE CASE LAST CHANGED(AAE), CLASS OF CASE(AAY),
ACCESSION YEAR(AAY1), ACCESSION NUMBER(AC), ACCESSION YEAR(ACAY), SITE/GP(ACF), PRIMARY SURGEON(ACP),
FOLLOWING PHYSICIAN(ACP), MANAGING PHYSICIAN(ACP), PHYSICIAN #3(ACP), PHYSICIAN #4(ACP), PHYSICIAN STAGING(ACP),
LAST TUMOR STATUS(ACS), PRIMARY SITE(AD), DATE DX(ADX), ACCESSION NUMBER(AE), HEMA TRANS/ENDOCRINE PROC(AE),
HEMA TRANS/ENDOCRINE PROC @FAC(AE), ACCESSION NUMBER(AF), DATE OF FIRST CONTACT(AFC), FOLLOWING PHYSICIAN(AFP),
CLASS CATEGORY(AG), HISTOLOGY (ICD-O-2)(AH), SURGERY OF PRIMARY (R)(AI), RX SUMM--SURG PRIMSITE 03-2022(AI),
RADIATION(AJ), DATE OF NO TREATMENT(AK), HISTOLOGY (ICD-O-3)(AL), CHEMOTHERAPY(AM), MANAGING PHYSICIAN(AMP),
PALLIATIVE CARE(AN), HORMONE THERAPY(AN), IMMUNOTHERAPY(AO), PHYSICIAN #3(AOP3), PHYSICIAN #4(AOP4),
OTHER TREATMENT(AP), PRIMARY SURGEON(APC), FOLLOWING PHYSICIAN(APC), MANAGING PHYSICIAN(APC), PHYSICIAN #3(APC),
PHYSICIAN #4(APC), PHYSICIAN STAGING(APC), PCE INDICATOR(APCE), PRIMARY SURGEON(APS), PHYSICIAN STAGING(APST),
SURGICAL DX/STAGING PROC(AQ), SURG DX/STAGING PROC @FAC(AR), ABSTRACT STATUS(AS), STAGE GROUP CLINICAL(AS1),
STAGE GROUP PATHOLOGIC(AS2), SCOPE OF LN SURGERY (R)(ASC), SCOPE OF LN SURGERY (F)(ASC),
SCOPE OF LN SURGERY @FAC (R)(ASCF), SCOPE OF LN SURGERY @FAC (F)(ASCF), STAGE GROUPING-AJCC(ASG),
SURG PROC/OTHER SITE (R)(ASO), SURG PROC/OTHER SITE (F)(ASO), SURG PROC/OTHER SITE @FAC (R)(ASOF),
SURG PROC/OTHER SITE @FAC (F)(ASOF), SURGERY OF PRIMARY @FAC (R)(AT), RX HOSP--SURG PRIMSITE 03-2022(AT),
IMMUNOTHERAPY DATE(ATB), CHEMOTHERAPY DATE(ATC), HEMA TRANS/ENDOCRINE PROC DATE(ATE), HORMONE THERAPY DATE(ATH),
DATE OF NO TREATMENT(ATN), OTHER TREATMENT START DATE(ATO), RADIATION THERAPY TO CNS DATE(ATP),
DATE RADIATION STARTED(ATR), MOST DEFINITIVE SURG DATE(ATS), SCOPE OF LN SURGERY DATE(ATSC),
DATE FIRST SURGICAL PROCEDURE(ATSF), SURG PROC/OTHER SITE DATE(ATSO), RADIATION @FACILITY(AU),
CHEMOTHERAPY @FAC(AV), HORMONE THERAPY @FAC(AW), IMMUNOTHERAPY @FAC(AX), ACCESSION YEAR(AY),
OTHER TREATMENT @FAC(AZ), SITE/GP(B), PRIMARY SITE(BT), PATIENT NAME(C), SEQUENCE NUMBER(D),
ACCESSION NUMBER(D1), PRIMARY SITE(E), SURGERY OF PRIMARY SITE(F), AJCC TNM CLIN STAGE GROUP(G),
AJCC TNM PATH STAGE GROUP(H), LYMPH NODES(SS1)
^ONCO(165.5,D0,0)= (#.01) SITE/GP [1P:164.2] ^ (#.02) PATIENT NAME [2P:160] ^ (#.03) REPORTING FACILITY [3P:160.19] ^ (#.04)
==>CLASS OF CASE [4P:165.3] ^ (#.05) ACCESSION NUMBER [5F] ^ (#.06) SEQUENCE NUMBER [6F] ^ (#.07) ACCESSION YEAR
==>[7F] ^ (#1) DATE OF INPATIENT ADMISSION [8D] ^ (#1.1) DATE OF INPATIENT DISCHARGE [9D] ^ (#1.2) TYPE OF
==>REPORTING SOURCE [10P:168] ^ (#2) PRIMARY SURGEON [11P:165] ^ (#2.1) FOLLOWING PHYSICIAN [12P:165] ^ (#2.2)
==>MANAGING PHYSICIAN [13P:165] ^ (#2.3) PHYSICIAN #3 [14P:165] ^ (#2.4) PHYSICIAN #4 [15P:165] ^ (#3) DATE DX
==>[16D] ^ (#5) DX FACILITY [17P:160.19] ^ (#6) FACILITY REFERRED FROM [18P:160.19] ^ (#7) FACILITY REFERRED TO
==>[19P:160.19] ^ (#.042) CLASS CATEGORY [20S] ^ (#83) AFIP/JPC SUBMISSION [21S] ^ (#.022) ICDO-SITE [22P:164.08]
==>^ (#123) INPATIENT/OUTPATIENT STATUS [23S] ^ (#79) SCREENING DATE [24D] ^ (#119) SCREENING RESULT [25S] ^
==>(#120) PRESENTATION AT CANCER CONF [26S] ^ (#121) DATE OF CANCER CONF [27D] ^ (#122) REFERRAL TO SUPPORT
==>SERVICES [28S] ^ (#147) CENSUS TRACT [29F] ^ (#148) OTHER CANCER [30S] ^ (#148.1) CANCER #1 [31P:164.2] ^
==>(#148.2) CANCER #2 [32P:164.2] ^ (#148.3) CANCER #3 [33P:164.2] ^ (#148.4) CANCER #4 [34P:164.2] ^ (#155) DATE
==>OF FIRST CONTACT [35D] ^
^ONCO(165.5,D0,1)= (#8) PATIENT ADDRESS AT DX [1F] ^ (#9) POSTAL CODE AT DX [2F] ^ (#10) COUNTY AT DX [3F] ^ (#16) STATE AT DX
==>[4P:5] ^ (#11) MARITAL STATUS AT DX [5S] ^ (#21) CASEFINDING SOURCE [6P:166] ^ (#227) PERFORMANCE STATUS AT DX
==>[7S] ^ ^ ^ (#17) SUSPENSE DATE [10D] ^ (#18) PRIMARY PAYER AT DX [11P:160.3] ^ (#8.1) CITY/TOWN AT DX [12F]
==>^ (#8.2) PATIENT ADDRESS AT DX - SUPP [13F] ^
^ONCO(165.5,D0,2)= (#20) PRIMARY SITE [1P:164] ^ ^ (#22) HISTOLOGY (ICD-O-2) [3P:164.1] ^ (#22.2) PAPILLARY/FOLLICULAR [4S] ^
==>(#24) GRADE/DIFFERENTIATION [5P:164.43] ^ (#26) DIAGNOSTIC CONFIRMATION [6S] ^ (#21.5) INFRA/SUPRA [7S] ^
==>(#28) LATERALITY [8S] ^ (#29) TUMOR SIZE [9N] ^ (#30) EXTENSION [10N] ^ (#31) LYMPH NODES [11N] ^ (#32)
==>REGIONAL LYMPH NODES POSITIVE [12N] ^ (#33) REGIONAL LYMPH NODES EXAMINED [13N] ^ (#34) SITE OF DISTANT
==>METASTASIS #1 [14S] ^ (#34.1) SITE OF DISTANT METASTASIS #2 [15S] ^ (#34.2) SITE OF DISTANT METASTASIS #3
==>[16S] ^ (#35) SEER SUMMARY STAGE 2000 [17S] ^ (#36) AJCC STAGING BASIS [18S] ^ (#149) LYMPH-VASCULAR INVASION
==>(L) [19S] ^ (#38) STAGE GROUP CLINICAL [20F] ^ (#39) OTHER STAGING SYSTEM [21P:164.3] ^ (#21.51) IRIS/CILIARY
==>BODY [22S] ^ (#41) ASSOCIATED WITH HIV [23S] ^ (#45) PERFORMANCE STATUS [24S] ^ (#37.1) CLINICAL T [25F] ^
==>(#37.2) CLINICAL N [26F] ^ (#37.3) CLINICAL M [27F] ^ (#38.5) STAGE GROUPING-AJCC [28S] ^ (#151) VENOUS
==>INVASION (V) [29S] ^ ^ (#69) MULTIPLE TUMORS [31N] ^ (#69.1) FAMILY HISTORY [32S] ^
^ONCO(165.5,D0,2.1)= (#85) PATHOLOGIC T [1F] ^ (#86) PATHOLOGIC N [2F] ^ (#87) PATHOLOGIC M [3F] ^ (#88) STAGE GROUP PATHOLOGIC
==>[4F] ^ (#89) STAGED BY (PATHOLOGIC STAGE) [5P:165.7] ^ (#93) OTHER T [6F] ^ (#98) OTHER N [7F] ^ (#99) OTHER
==>M [8F] ^ (#117) OTHER STAGE GROUP [9F] ^ (#118) STAGED BY (OTHER STAGE) [10S] ^ (#124) DATE OF NO TREATMENT
==>[11D] ^ (#134) CLINICAL RISK FACTORS [12S] ^ (#135) PATHOLOGIC RISK FACTORS [13S] ^ (#141) BIOPSY PROCEDURE
==>[14N] ^ (#142) GUIDANCE [15N] ^ (#143) PALPABILITY OF PRIMARY [16S] ^ (#144) FIRST DETECTED BY [17S] ^
==>(#145) APPROACH FOR BIOPSY OF PRIMARY [18S] ^ (#146) BIOPSY OF OTHER THAN PRIMARY [19S] ^ (#29.3) TUMOR SIZE
==>SUMMARY [20N] ^ (#29.4) TUMOR SIZE CLINICAL [21N] ^ (#29.5) TUMOR SIZE PATHOLOGIC [22N] ^
^ONCO(165.5,D0,2.2)= (#137) DATE OF 1ST POSITIVE BIOPSY [1D] ^ (#30.1) PATHOLOGIC EXTENSION [2N] ^ (#22.3) HISTOLOGY (ICD-O-3)
==>[3P:169.3] ^ (#171) DATE OF FIRST SYMPTOMS [4F] ^ (#172) DATE START OF WORKUP ORDERED [5F] ^ (#173) DATE
==>WORKUP STARTED [6F] ^ (#174) BLOOD IN SPUTUM PER PT [7S] ^ (#175) CHEST X-RAY [8S] ^ (#176) CT SCAN [9S] ^
==>(#177) BRONCHOSCOPY [10S] ^ (#178) MEDIASTINOSCOPY [11S] ^ (#179) PET SCAN [12S] ^ (#180) CHANGE IN BOWEL
==>HABITS PER PT [13S] ^ (#181) FECAL OCCULT BLOOD TEST (FOBT) [14S] ^ (#182) BARIUM ENEMA [15S] ^ (#183)
==>SIGMOIDOSCOPY [16S] ^ (#184) CT OF ABDOMEN/PELVIS [17S] ^ (#174.1) DATE OF BLOOD IN SPUTUM PER PT [18F] ^
==>(#175.1) DATE OF CHEST X-RAY [19F] ^ (#176.1) DATE OF CT SCAN [20F] ^ (#177.1) DATE OF BRONCHOSCOPY [21F] ^
==>(#178.1) DATE OF MEDIASTINOSCOPY [22F] ^ (#179.1) DATE OF PET SCAN [23F] ^ (#180.1) DATE OF CHANGE IN BOWEL
==>HABITS [24F] ^ (#181.1) DATE OF FOBT [25F] ^ ^ (#182.1) DATE OF BARIUM ENEMA [27F] ^ (#183.1) DATE OF
==>SIGMOIDOSCOPY [28F] ^ (#185) COLONOSCOPY [29S] ^ (#185.1) DATE OF COLONOSCOPY [30F] ^ (#184.1) DATE OF CT OF
==>ABDOMEN/PELVIS [31F] ^ (#186) DYSPNEA [32S] ^ (#186.1) DATE OF DYSPNEA [33F] ^ (#187) INCREASED COUGH [34S]
==>^ (#187.1) DATE OF INCREASED COUGH [35F] ^ (#188) FEVER [36S] ^ (#188.1) DATE OF FEVER [37F] ^ (#189) NIGHT
==>SWEATS [38S] ^ (#189.1) DATE OF NIGHT SWEATS [39F] ^ (#190) WEIGHT LOSS PER PT [40S] ^ (#191) ULCERATIVE
==>COLITIS (UC) [41S] ^ (#192) SPORADIC POLYPS [42S] ^
^ONCO(165.5,D0,2.3)= (#24.1) GRADE PATH SYSTEM [1S] ^ (#24.2) GRADE PATH VALUE [2S] ^ (#233) INPATIENT STATUS [3S] ^ (#234) RX
==>HOSP--SURG APP 2010 [4S] ^ (#235) TREATMENT STATUS [5S] ^ (#236) DATE CASE INITIATED [6D] ^ (#237) FEE BASIS
==>[7S] ^ (#238) OUTSIDE SLIDES REVIEWED [8S] ^ (#239) MITOTIC RATE [9S] ^ (#244) INITIATED BY [10P:200] ^
==>(#237.1) FEE BASIS LOCATION [11F] ^ (#24.3) GRADE CLINICAL [12F] ^ (#24.4) GRADE PATHOLOGICAL [13F] ^
==>(#24.5) GRADE POST THERAPY PATH (YP) [14F] ^ (#24.6) GRADE POST THERAPY CLIN (YC) [15F] ^
^ONCO(165.5,D0,3)= (#50) MOST DEFINITIVE SURG DATE [1D] ^ (#50.1) SURGERY HOSPITAL [2P:160.19] ^ ^ (#51) DATE RADIATION STARTED
==>[4D] ^ (#51.1) RADIATION HOSPITAL [5P:160.19] ^ (#51.2) RADIATION [6S] ^ (#51.3) RADIATION/SURGERY SEQUENCE
==>[7S] ^ (#52) RADIATION THERAPY TO CNS DATE [8D] ^ (#52.1) RADIATION THERAPY TO CNS HOSP [9P:160.19] ^ (#52.2)
==>RADIATION THERAPY TO CNS [10S] ^ (#53) CHEMOTHERAPY DATE [11D] ^ (#53.1) CHEMOTHERAPY HOSPITAL [12P:160.19] ^
==>(#53.2) CHEMOTHERAPY [13S] ^ (#54) HORMONE THERAPY DATE [14D] ^ (#54.1) HORMONE THERAPY HOSPITAL [15P:160.19]
==>^ (#54.2) HORMONE THERAPY [16S] ^ (#55) IMMUNOTHERAPY DATE [17D] ^ (#55.1) IMMUNOTHERAPY HOSPITAL [18P:160.19]
==>^ (#55.2) IMMUNOTHERAPY [19S] ^ (#56) NUMBER OF TXS TO THIS VOLUME [20N] ^ (#125) RADIATION TREATMENT VOLUME
==>[21P:164.7] ^ (#126) LOCATION OF RADIATION TX [22S] ^ (#57) OTHER TREATMENT START DATE [23D] ^ (#57.1) OTHER
==>TREATMENT HOSPITAL [24P:160.19] ^ (#57.2) OTHER TREATMENT [25S] ^ (#58) REASON NO SURGERY OF PRIMARY [26S] ^
==>(#58.1) SURGICAL DX/STAGING PROC [27F] ^ (#59) SURGICAL MARGINS [28S] ^ (#127) INTENT OF RADIATION [29S] ^
==>(#69.2) DIFFUSE RETINAL INVOLVEMENT [30S] ^ (#58.3) SURGICAL DX/STAGING PROC DATE [31D] ^ (#19) STAGED BY
==>(CLINICAL STAGE) [32P:165.7] ^ (#23) RECONSTRUCTION/RESTORATION [33F] ^ (#74) SURGICAL APPROACH (R) [34N] ^
==>(#75) REASON FOR NO RADIATION [35S] ^ (#76) REASON FOR NO CHEMOTHERAPY [36S] ^ (#77) REASON FOR NO HORMONE
==>THERAPY [37S] ^ (#58.2) SURGERY OF PRIMARY (R) [38N] ^ (#128) RADIATION COMPLETION STATUS [39P:164.8] ^ (#138)
==>SCOPE OF LN SURGERY (R) [40N] ^ (#139) SURG PROC/OTHER SITE (R) [41N] ^ (#140) NUMBER OF LN REMOVED (R) [42N]
==>^
^ONCO(165.5,D0,3.1)= (#129) RADIATION AUXILIARY VOLUME [1P:164.7] ^ (#130) RADIATION AUXILIARY DATE [2D] ^ (#132) RADIATION LOCAL
==>CONTROL STATUS [3S] ^ (#133) YEAR PUT ON PROTOCOL [4F] ^ (#58.4) SURG DX/STAGING PROC @FAC [5F] ^ (#58.5)
==>SURG DX/STAGING PROC @FAC DATE [6D] ^ (#50.2) SURGERY OF PRIMARY @FAC (R) [7F] ^ (#50.3) MOST DEFINITIVE
==>SURG @FAC DATE [8D] ^ (#138.1) SCOPE OF LN SURGERY @FAC (R) [9F] ^ (#139.1) SURG PROC/OTHER SITE @FAC (R)
==>[10F] ^ (#140.1) NUMBER OF LN REMOVED @FAC (R) [11F] ^ (#51.4) RADIATION @FACILITY [12S] ^ (#51.5) RADIATION
==>@FACILITY DATE [13D] ^ (#53.3) CHEMOTHERAPY @FAC [14S] ^ (#53.4) CHEMOTHERAPY @FAC DATE [15D] ^ (#54.3)
==>HORMONE THERAPY @FAC [16S] ^ (#54.4) HORMONE THERAPY @FAC DATE [17D] ^ (#55.3) IMMUNOTHERAPY @FAC [18S] ^
==>(#55.4) IMMUNOTHERAPY @FAC DATE [19D] ^ (#57.3) OTHER TREATMENT @FAC [20S] ^ (#57.4) OTHER TREATMENT
==>@FACILITY DATE [21D] ^ (#138.2) SCOPE OF LN SURGERY DATE [22D] ^ (#138.3) SCOPE OF LN SURGERY @FAC DATE
==>[23D] ^ (#139.2) SURG PROC/OTHER SITE DATE [24D] ^ (#139.3) SURG PROC/OTHER SITE @FAC DATE [25D] ^ (#12)
==>PALLIATIVE CARE [26S] ^ (#13) PALLIATIVE CARE @FAC [27S] ^ (#14) READMISSION W/I 30 DAYS/SURG [28S] ^
==>(#58.6) RX SUMM--SURG PRIMSITE 03-2022 [29F] ^ (#58.7) RX HOSP--SURG PRIMSITE 03-2022 [30F] ^ (#138.4) SCOPE
==>OF LN SURGERY (F) [31S] ^ (#138.5) SCOPE OF LN SURGERY @FAC (F) [32S] ^ (#139.4) SURG PROC/OTHER SITE (F)
==>[33S] ^ (#139.5) SURG PROC/OTHER SITE @FAC (F) [34S] ^ (#153.1) HEMA TRANS/ENDOCRINE PROC DATE [35D] ^
==>(#153) HEMA TRANS/ENDOCRINE PROC [36P:167] ^ (#154) PAIN ASSESSMENT [37S] ^ (#170) DATE FIRST SURGICAL
==>PROCEDURE [38D] ^ (#15) SYSTEMIC/SURGERY SEQUENCE [39S] ^ (#245) NEOADJUVANT THERAPY (PRE-2021) [40S] ^
==>(#139.6) METS SITE RESECTED [41S] ^
^ONCO(165.5,D0,3.2)= (#139.7) METS SITE RESECTED DATE [1D] ^ (#153.2) HEMA TRANS/ENDOCRINE PROC @FAC [2P:167] ^ (#153.3) HEMA
==>TRANS/ENDOCRINE PR@FAC DT [3D] ^ (#10104) RX HOSP--SURG BREAST [4F] ^ (#10105) RX SUMM--SURG BREAST [5F] ^
==>(#10106) RX HOSP--RECON BREAST [6F] ^ (#10107) RX SUMM--RECON BREAST [7F] ^ (#58.8) RX HOSP--SURG PRIM SITE
==>2023 [8F] ^ (#58.9) RX SUMM--SURG PRIM SITE 2023 [9F] ^
^ONCO(165.5,D0,4,0)=^165.51DA^^ (#60) SUBSEQUENT COURSE OF TREATMENT
^ONCO(165.5,D0,4,D1,0)= (#.01) INITIATION DATE [1D] ^ (#1) RADIATION SEQUENCE [2S] ^ (#2) PLACE [3P:160.19] ^ (#.04) SURGERY OF
==>PRIMARY SITE [4N] ^ (#.05) RADIATION [5S] ^ (#.06) CHEMOTHERAPY [6S] ^ (#.07) HORMONE THERAPY [7S] ^
==>(#.08) IMMUNOTHERAPY [8S] ^ (#.09) OTHER TREATMENT [9S] ^ (#.03) RADIATION THERAPY TO CNS [10S] ^ (#.041)
==>SURGERY OF PRIMARY SITE DATE [11D] ^ (#.051) RADIATION DATE [12D] ^ (#.061) CHEMOTHERAPY DATE [13D] ^
==>(#.071) HORMONE THERAPY DATE [14D] ^ (#.081) IMMUNOTHERAPY DATE [15D] ^ (#.091) OTHER TREATMENT START
==>DATE [16D] ^ (#.031) RADIATION THERAPY TO CNS DATE [17D] ^ (#.02) HEMA TRANS/ENDOCRINE PROC [18P:167] ^
==>(#.021) HEMA TRANS/ENDOCRINE PROC DATE [19D] ^
^ONCO(165.5,D0,4,D1,1,0)=^165.513^^ (#3) SUBSEQUENT THERAPY COMMENTS
^ONCO(165.5,D0,4,D1,1,D2,0)= (#.01) COMMENTS [1W] ^
^ONCO(165.5,D0,4,D1,2)= (#4) INTERSTITIAL RADIATION [1S] ^ (#5) IODINE 125 [2S] ^ (#6) GOLD 198 [3S] ^ (#7) PALLADIUM 103 [4S] ^
==>(#8) IRIDIUM 192 [5S] ^ (#9) OTHER INTERSTITIAL, NOS [6S] ^ (#10) EXTERNAL RADIATION [7S] ^ (#11)
==>PROSTATE REGION ONLY [8S] ^ (#12) PROSTATE AND PELVIC NODES [9S] ^ (#13) PROSTATE & PELVIC PARA-AORTIC
==>[10S] ^ (#14) DISTANT METASTATIC SITES [11S] ^ (#15) OTHER EXTERNAL SITES, NOS [12S] ^ (#16) RADIATION
==>PLANNED/GIVEN [13S] ^ (#17) TOTAL RAD DOSE (PROSTATE) [14S] ^ (#18) TOTAL RAD DOSE (PELVIC NODES) [15S] ^
==>(#19) TOTAL RAD DOSE (PARA-AORTIC) [16S] ^ (#20) CHEMOTHERAPY PLANNED/GIVEN [17S] ^ (#21) ADRIAMYCIN
==>[18S] ^ (#22) CYTOXAN [19S] ^ (#23) METHOTREXATE [20S] ^ (#24) 5-FLUOROURACIL [21S] ^ (#25) OTHER [22S] ^
==>(#26) HORMONE THERAPY PLANNED/GIVEN [23S] ^ (#27) ESTROGENS [24S] ^ (#28) ANTIANDROGENS [25S] ^ (#29)
==>PROGESTATIONAL AGENTS [26S] ^ (#30) LUTEINIZING HORMONE-RELEASING [27S] ^ (#31) ORCHIECTOMY [28S] ^ (#32)
==>OTHER HORMONES [29S] ^ (#33) RECON/RESTORE - DELAYED [30N] ^ (#34) RECON/RESTORE - DELAYED DATE [31D] ^
==>(#35) SCOPE OF LYMPH NODE SURGERY [32S] ^ (#36) SURGICAL PROC/OTHER SITE [33S] ^ (#37) NUMBER OF NODES
==>REMOVED [34N] ^ (#38) SCOPE OF LN SURGERY DATE [35D] ^ (#39) SURGICAL PROC/OTHER SITE DATE [36D] ^ (#40)
==>METS SITE RESECTED [37S] ^ (#41) METS SITE RESECTED DATE [38D] ^ (#42) PALLIATIVE CARE [39S] ^
^ONCO(165.5,D0,5)= (#70) DATE OF FIRST RECURRENCE [1D] ^ (#71) TYPE OF FIRST RECURRENCE [2P:160.12] ^ (#71.1) DISTANT SITE 1 [3S]
==>^ (#71.2) DISTANT SITE 2 [4S] ^ (#71.3) DISTANT SITE 3 [5S] ^ (#71.4) OTHER TYPE OF FIRST RECURRENCE
==>[6P:160.12] ^
^ONCO(165.5,D0,6,0)=^165.52A^^ (#80) RADIATION TREATMENT
^ONCO(165.5,D0,6,D1,0)= (#.01) TARGET PLACE [1F] ^ (#1) TARGET SITE [2P:164] ^ (#2) RADIATION SOURCE [3S] ^ (#3) TOTAL DOSE TO
==>TARGET (cGy) [4N] ^ (#4) # FRACTIONS [5N] ^ (#5) PREDOMINANT FXN SIZE (cGy) [6N] ^ (#6) # DAYS [7N] ^
==>(#7) START DATE [8D] ^ (#8) STOP DATE [9D] ^
^ONCO(165.5,D0,6,D1,1,0)=^165.529^^ (#9) TEXT
^ONCO(165.5,D0,6,D1,1,D2,0)= (#.01) TEXT [1W] ^
^ONCO(165.5,D0,7)= (#90) DATE CASE COMPLETED [1D] ^ (#91) ABSTRACT STATUS [2S] ^ (#92) ABSTRACTED BY [3P:200] ^ (#62) QA SELECTED
==>[4S] ^ (#94) REPORTING DATE [5D] ^ (#95) LAST TUMOR STATUS [6P:164.42] ^ (#25) TNM FORM ASSIGNED [7F] ^ (#63)
==>QA REVIEW [8S] ^ (#64) QA DATE [9D] ^ (#65) PHYSICIAN'S STAGE [10F] ^ (#66) PHYSICIAN STAGING [11P:165] ^
==>(#81) COMPLETED BY [12F] ^ (#82) REVIEWED BY CANCER COMMITTEE [13F] ^ (#44) TNM FORM COMPLETED [14F] ^ (#84)
==>PCE INDICATOR [15S] ^ (#69.3) MULTIMODALITY THERAPY (CLIN) [16S] ^ (#69.4) MULTIMODALITY THERAPY [17S] ^
==>(#64.1) QA REVIEWER [18P:200] ^ (#46) CAP PROTOCOL REVIEW [19S] ^ (#47) CAP TEXT [20F] ^ (#198) DATE CASE LAST
==>CHANGED [21D] ^ (#199) CASE LAST CHANGED BY [22P:200] ^
^ONCO(165.5,D0,8)= (#100) TEXT-PRIMARY SITE TITLE [1F] ^ (#101) TEXT-HISTOLOGY TITLE [2F] ^
^ONCO(165.5,D0,9,0)=^165.5103A^^ (#103) TEXT-DX PROC-OP
^ONCO(165.5,D0,9,D1,0)= (#.01) TEXT-DX PROC-OP [1W] ^
^ONCO(165.5,D0,10,0)=^165.5104A^^ (#104) TEXT-DX PROC-PE
^ONCO(165.5,D0,10,D1,0)= (#.01) TEXT-DX PROC-PE [1W] ^
^ONCO(165.5,D0,11,0)=^165.5105A^^ (#105) TEXT-DX PROC-X-RAY/SCAN
^ONCO(165.5,D0,11,D1,0)= (#.01) TEXT-DX PROC-X-RAY/SCAN [1W] ^
^ONCO(165.5,D0,12,0)=^165.5106A^^ (#106) TEXT-DX PROC-SCOPES
^ONCO(165.5,D0,12,D1,0)= (#.01) TEXT-DX PROC-SCOPES [1W] ^
^ONCO(165.5,D0,13,0)=^165.5107A^^ (#107) TEXT-DX PROC-PATH
^ONCO(165.5,D0,13,D1,0)= (#.01) TEXT-DX PROC-PATH [1W] ^
^ONCO(165.5,D0,14,0)=^165.5108A^^ (#108) RX TEXT-SURGERY
^ONCO(165.5,D0,14,D1,0)= (#.01) RX TEXT-SURGERY [1W] ^
^ONCO(165.5,D0,15,0)=^165.5109A^^ (#109) RX TEXT-RADIATION
^ONCO(165.5,D0,15,D1,0)= (#.01) RX TEXT-RADIATION (BEAM) [1W] ^
^ONCO(165.5,D0,15.1,0)=^165.5131^^ (#131) RADIATION AUXILIARY TEXT
^ONCO(165.5,D0,15.1,D1,0)= (#.01) RADIATION AUXILIARY TEXT [1W] ^
^ONCO(165.5,D0,16,0)=^165.53A^^ (#110) RX TEXT-RADIATION OTHER
^ONCO(165.5,D0,16,D1,0)= (#.01) RX TEXT-RADIATION OTHER [1W] ^
^ONCO(165.5,D0,17,0)=^165.5111A^^ (#111) RX TEXT-CHEMO
^ONCO(165.5,D0,17,D1,0)= (#.01) RX TEXT-CHEMO [1W] ^
^ONCO(165.5,D0,18,0)=^165.5112A^^ (#112) RX TEXT-HORMONE
^ONCO(165.5,D0,18,D1,0)= (#.01) RX TEXT-HORMONE [1W] ^
^ONCO(165.5,D0,19,0)=^165.5113A^^ (#113) TEXT-REMARKS
^ONCO(165.5,D0,19,D1,0)= (#.01) TEXT-REMARKS [1W] ^
^ONCO(165.5,D0,20,0)=^165.5114A^^ (#114) RX TEXT-BRM
^ONCO(165.5,D0,20,D1,0)= (#.01) RX TEXT-BRM [1W] ^
^ONCO(165.5,D0,21,0)=^165.5115A^^ (#115) RX TEXT-OTHER
^ONCO(165.5,D0,21,D1,0)= (#.01) RX TEXT-OTHER [1W] ^
^ONCO(165.5,D0,22,0)=^165.5116A^^ (#116) TEXT-DX PROC-LAB TESTS
^ONCO(165.5,D0,22,D1,0)= (#.01) TEXT-DX PROC-LAB TESTS [1W] ^
^ONCO(165.5,D0,22.1,0)=^165.5285^^ (#285) TEXT-STAGING
^ONCO(165.5,D0,22.1,D1,0)= (#.01) TEXT-STAGING [1W] ^
^ONCO(165.5,D0,22.2,0)=^165.5286^^ (#286) TEXT-SITE SPECIFIC DATA ITEMS
^ONCO(165.5,D0,22.2,D1,0)= (#.01) TEXT-SITE SPECIFIC DATA ITEMS [1W] ^
^ONCO(165.5,D0,22.3,0)=^165.5287^^ (#287) TEXT-COVID-19
^ONCO(165.5,D0,22.3,D1,0)= (#.01) TEXT-COVID-19 [1W] ^
^ONCO(165.5,D0,22.4,0)=^165.5289^^ (#289) TEXT-HIV, SCA, DRUG & ETOH
^ONCO(165.5,D0,22.4,D1,0)= (#.01) TEXT-HIV, SCA, DRUG & ETOH [1W] ^
^ONCO(165.5,D0,23,0)=^165.572D^^ (#72) SUBSEQUENT RECURRENCES
^ONCO(165.5,D0,23,D1,0)= (#.01) DATE of SUBSEQUENT RECURRENCE [1D] ^ (#.02) TYPE of SUBSEQUENT RECURRENCE [2P:160.12] ^ (#.03)
==>DISTANT SITE 1 [3S] ^ (#.031) DISTANT SITE 2 [4S] ^ (#.032) DISTANT SITE 3 [5S] ^ (#1) OTHER T [6F] ^
==>(#2) OTHER N [7F] ^ (#3) OTHER M [8F] ^ (#4) OTHER STAGE GROUP [9F] ^ (#5) STAGED BY (OTHER STAGE) [10S]
==>^
^ONCO(165.5,D0,24)= (#37.9) AUTOMATIC STAGING OVERRIDDEN [1S] ^ (#25.1) TUMOR MARKER 1 [2P:164.15] ^ (#25.2) TUMOR MARKER 2
==>[3P:164.15] ^ (#21.52) UPPER/LOWER [4S] ^ (#30.5) PERIPHERAL BLOOD INVOLVEMENT [5S] ^ (#78) CONVERTED [6S] ^
==>(#25.3) TUMOR MARKER 3 [7P:164.15] ^ (#136) SERUM TUMOR MARKERS [8S] ^ (#363.1) BOOST TREATMENT MODALITY
==>[9P:166.13] ^ (#102) DRE +/- [10S] ^ (#156) DRE DATE [11F] ^ (#159) AMBIGUOUS TERMINOLOGY DX [12S] ^ (#193)
==>DATE OF CONCLUSIVE DX [13F] ^ (#194) MULT TUM RPT AS ONE PRIM [14P:169] ^ (#195) DATE OF MULTIPLE TUMORS
==>[15F] ^ (#196) MULTIPLICITY COUNTER [16F] ^ (#228) TREATMENT GUIDELINE #1 [17S] ^ (#229) TREATMENT GUIDELINE
==>#2 [18S] ^ (#230) TREATMENT GUIDELINE #3 [19S] ^ (#231) TREATMENT GUIDELINE LOCATION [20F] ^ (#232) TREATMENT
==>GUIDELINE DOC DATE [21D] ^ (#241) TNM CLIN DESCRIPTOR [22S] ^ (#242) TNM PATH DESCRIPTOR [23S] ^
^ONCO(165.5,D0,25)= (#248) NOTE TITLE [1F] ^ (#249) NOTE DATE [2D] ^ (#250) GLEASON SCORE (PATHOLOGIC) [3F] ^ (#279) CLINICAL
==>TRIALS DISCUSSION [4S] ^ (#280) CLIN TNM DOCUMENTATION PRE-TX [5S] ^ (#281) TX GUIDELINES DISCUSSION [6S] ^
==>(#280.1) CL TNM DOCUMENTATION LOCATION [7F] ^ (#280.2) CL TNM DOCUMENTATION DATE [8D] ^ (#284) UDF1 [9F] ^
==>(#284.1) UDF2 [10F] ^ (#284.2) UDF3 [11F] ^ (#284.3) UDF4 [12F] ^ (#284.4) UDF5 [13F] ^ (#284.5) UDF6 [14F] ^
==>(#284.6) UDF7 [15F] ^ (#284.7) UDF8 [16F] ^ (#284.8) UDF9 [17F] ^ (#284.9) UDF10 [18F] ^ (#78.1) CONVERTED
==>STAGED BY FIELDS [19S] ^ (#78.2) CONVERTED TNM FIELDS [20S] ^ (#288) TOBACCO USE SMOKING STATUS [21S] ^
^ONCO(165.5,D0,27)= (#997) STAGE FLAG [1S] ^ (#996) SURGICAL MARGINS CONV FLAG [2S] ^ (#998) SCOPE OF LN SURGERY CONV FLAG [3S] ^
==>(#999) SURGICAL PROC/OTHER CONV FLAG [4S] ^ (#995) STAGED BY CONV FLAG [5S] ^ (#994) TYPE OF FIRST RECUR CONV
==>FLAG [6S] ^ (#993) REGIONAL TX MODALITY CONV FLAG [7S] ^ (#999.1) DATE OF DIAGNOSIS FLAG [8N] ^ (#999.2) DATE
==>CONCLUSIVE DX FLAG [9N] ^ (#999.3) DATE OF MULT TUMORS FLAG [10N] ^ (#999.4) DATE OF FIRST CONTACT FLAG [11N]
==>^ (#999.5) DATE OF INPT ADM FLAG [12N] ^ (#999.6) DATE OF INPT DISCH FLAG [13N] ^ (#999.7) DATE 1ST CRS RX
==>FLAG [14N] ^ (#999.8) RX DATE-SURGERY FLAG [15N] ^ (#999.9) RX DATE MST DEFN SRG FLAG [16N] ^ (#999.11) RX
==>DATE SURG DISCH FLAG [17N] ^ (#999.12) RX DATE-RADIATION FLAG [18N] ^ (#999.13) RX DATE RAD ENDED FLAG [19N]
==>^ (#999.14) RX DATE SYSTEMIC FLAG [20N] ^ (#999.15) RX DATE-CHEMO FLAG [21N] ^ (#999.16) RX DATE-HORMONE FLAG
==>[22N] ^ (#999.17) RX DATE-BRM FLAG [23N] ^ (#999.18) RX DATE-OTHER FLAG [24N] ^ (#999.19) RX DATE-DX/STG PROC
==>FLAG [25N] ^ (#999.21) RECURRENCE DATE-1ST FLAG [26N] ^ (#999.22) DATE OF LAST CONTACT FLAG [27N] ^ (#999.23)
==>SUBSQ RX 2ND CRS DATE FLAG [28N] ^ (#999.24) SUBSQ RX 3RD CRS DATE FLAG [29N] ^ (#999.25) SUBSQ RX 4TH CRS
==>DATE FLAG [30N] ^ (#999.26) ADDRESS AT DX--STATE [31F] ^ (#999.27) ADDRESS AT DX--COUNTRY [32F] ^ (#999.28)
==>ADDRESS CURRENT--STATE [33F] ^ (#999.29) ADDRESS CURRENT--COUNTRY [34F] ^ (#999.289) ADDRESS CURRENT--POSTAL
==>CODE [35F] ^
^ONCO(165.5,D0,28,0)=^165.54^^ (#64.2) QA FINDINGS
^ONCO(165.5,D0,28,D1,0)= (#.01) QA FINDINGS [1W] ^
^ONCO(165.5,D0,AJCC8)= (#5000) AJCC ID [1F] ^ (#5001) AJCC TNM CLIN T [2F] ^ (#5002) AJCC TNM CLIN N [3F] ^ (#5003) AJCC TNM CLIN
==>M [4F] ^ (#5004) AJCC TNM CLIN STAGE GROUP [5F] ^ (#5011) AJCC TNM PATH T [6F] ^ (#5012) AJCC TNM PATH N
==>[7F] ^ (#5013) AJCC TNM PATH M [8F] ^ (#5014) AJCC TNM PATH STAGE GROUP [9F] ^ (#5021) AJCC TNM POST THER
==>(yp) T [10F] ^ (#5022) AJCC TNM POST THER (yp) N [11F] ^ (#5023) AJCC TNM POST THER (yp) M [12F] ^ (#5024)
==>AJCC TNM POST THER (yp) SG [13F] ^ (#5031) AJCC TNM CLIN T SUFFIX [14F] ^ (#5034) AJCC TNM CLIN N SUFFIX
==>[15F] ^ (#5032) AJCC TNM PATH T SUFFIX [16F] ^ (#5035) AJCC TNM PATH N SUFFIX [17F] ^ (#5033) AJCC TNM
==>POST THER (yp) T SFX [18F] ^ (#5036) AJCC TNM POST THER (yp) N SFX [19F] ^ (#5025) AJCC TNM POST THER (yc)
==>T [20F] ^ (#5026) AJCC TNM POST THER (yc) N [21F] ^ (#5027) AJCC TNM POST THER (yc) M [22F] ^ (#5028) AJCC
==>TNM POST THER (yc) SG [23F] ^ (#5033.5) AJCC TNM POST THER (yc) T SFX [24F] ^ (#5036.5) AJCC TNM POST THER
==>(yc) N SFX [25F] ^
^ONCO(165.5,D0,BLA1)= (#300) PATIENT REFERRED FOR TREATMENT [1S] ^ (#301) LENGTH OF STAY [2N] ^ (#302) HISTORY OF CERVIX CA (PT)
==>[3S] ^ (#303) HISTORY OF COLON CA (PT) [4S] ^ (#304) HISTORY OF BLADDER CA (PT) [5S] ^ (#305) HISTORY OF
==>HEAD & NECK CA (PT) [6S] ^ (#306) HISTORY OF KIDNEY CA (PT) [7S] ^ (#307) HISTORY OF PROSTATE CA (PT) [8S]
==>^ (#308) HISTORY OF OTHER CA (PT) [9S] ^ (#309) HISTORY OF BLADDER CA (FAM) [10S] ^ (#310) HISTORY OF COLON
==>CA (FAM) [11S] ^ (#311) HISTORY OF LUNG CA (FAM) [12S] ^ (#312) HISTORY OF PROSTATE CA (FAM) [13S] ^ (#313)
==>HISTORY OF OTHER CA (FAM) [14S] ^ (#314) SMOKING HISTORY [15N] ^ (#315) DURATION OF SMOKING HISTORY [16N] ^
==>(#316) DURATION OF SMOKE FREE HISTORY [17N] ^ (#317) GROSS HEMATURIA [18S] ^ (#318) MICROSCOPIC HEMATURIA
==>[19S] ^ (#319) URINARY FREQUENCY [20S] ^ (#320) BLADDER IRRITABILITY [21S] ^ (#321) DYSURIA [22S] ^ (#322)
==>OTHER CLINICAL DETECTIONS [23S] ^ (#323) ONSET OF SYMPTOMS [24D] ^ (#324) DURATION OF GROSS HEMATURIA [25N]
==>^ (#325) DURATION OF DYSURIA [26N] ^ (#326) BIMANAUL EXAM OF BLADDER [27S] ^ (#327) CYSTOSCOPY WITH BIOPSY
==>[28S] ^ (#328) CYSTOSCOPY WITHOUT BIOPSY [29S] ^ (#329) FLOW CYTOMETRY [30S] ^ (#330) INTRAVENOUS PYELOGRAM
==>(BLA) [31S] ^ (#331) URINE CYTOLOGY [32S] ^ (#332) URINALYSIS [33S] ^ (#333) OTHER DIAGNOSTIC PROCEDURES
==>[34S] ^ (#334) SPECIALTY MAKING DIAGNOSIS [35S] ^ (#335) ABDOMINAL ULTRASOUND [36S] ^ (#336) BONE IMAGING
==>[37S] ^ (#337) CHEST X-RAY (BLADDER) [38S] ^ (#338) CT CHEST/LUNG [39S] ^ (#339) CT ABDOMEN/PELVIS [40S] ^
==>(#340) CT OTHER [41S] ^ (#341) MRI PELVIS/ABDOMEN [42S] ^ (#342) MRI OTHER [43S] ^ (#343) OTHER STAGING
==>PROCEDURES [44S] ^ (#344) PRESENCE OF HYDRONEPHROSIS [45S] ^ (#345) PRESENCE OF MULTIPLE TUMORS [46S] ^
^ONCO(165.5,D0,BLA2)= (#346) PROTOCOL ELIGIBILITY STATUS [1S] ^ (#347) MANAGING PHYSICIAN (PRIMARY) [2P:166.12] ^ (#348) MANAGING
==>PHYSICIAN (SECONDARY) [3P:166.12] ^ (#349) TUMOR RESECTION DURING TURB [4S] ^ (#350) TYPE OF URINARY
==>DIVERSION [5S] ^ (#351) PELVIC LYMPH NODE DISSECT (BL) [6S] ^ (#352) BLEEDING REQUIRING TRANSFUSION [7S] ^
==>(#353) DEEP VENOUS THROMBOSIS [8S] ^ (#354) MYOCARDIAL INFARCTION (MI) [9S] ^ (#355) PELVIC ABSCESS [10S] ^
==>(#356) PNEUMONIA REQ ANTIBIOTICS [11S] ^ (#357) POST-OPERATIVE DEATH [12S] ^ (#358) PULMONARY
==>EMBOLISM/THROMBOSIS [13S] ^ (#359) REOPERATION [14S] ^ (#360) OTHER SURGICAL COMPLICATIONS [15S] ^ (#361)
==>DATE RADIATION ENDED [16D] ^ (#362) TOTAL RAD (cGy/rad) DOSE [17N] ^ (#363) REGIONAL TREATMENT MODALITY
==>[18P:166.13] ^ (#364) URINARY INCONTINENCE [19S] ^ (#365) HEMATURIA [20S] ^ (#366) RADIATION BOWEL INJURY
==>[21S] ^ (#367) DATE CHEMOTHERAPY ENDED [22D] ^ (#368) ROUTE CHEMOTHERAPY ADMIN [23S] ^ (#369) ADRIAMYCIN
==>[24S] ^ (#370) CARBOPLATINUM [25S] ^ (#371) CISPLATIN [26S] ^ (#372) CYCLOPHOSPHAMIDE [27S] ^ (#373)
==>5-FLUOROURACIL [28S] ^ (#374) GALLIUM NITRATE [29S] ^ (#375) IFOSFAMIDE [30S] ^ (#376) METHOTREXATE [31S] ^
==>(#377) TAXOL [32S] ^ (#378) THIOTEPA [33S] ^ (#379) VINBLASTINE [34S] ^ (#380) OTHER CHEMOTHERAPEUTIC
==>AGENTS [35S] ^ (#381) INDICATION FOR ADMIN OF AGENTS [36S] ^ (#383) BCG [37S] ^ (#384) INTERFERON [38S] ^
==>(#385) INTERLEUKIN-2 [39S] ^ (#386) OTHER TYPE OF IMMUNOTHERAPY [40S] ^ (#382) REASON CHEMOTHERAPY STOPPED
==>[41S] ^ (#387) TYPE OF 1ST RECURRENCE/BLADDER [42S] ^
^ONCO(165.5,D0,BRE1)= (#900) DAUGHTER (BR98) [1S] ^ (#901) MATERNAL AUNT (BR98) [2S] ^ (#902) MATERNAL GRANDMOTHER (BR98) [3S] ^
==>(#903) MOTHER (BR98) [4S] ^ (#904) ONE SISTER (BR98) [5S] ^ (#905) MORE THAN ONE SISTER (BR98) [6S] ^
==>(#906) FATHER (BR98) [7S] ^ (#907) BROTHER (BR98) [8S] ^ (#908) FAM HISTORY BREAST CA (BR98) [9S] ^ (#909)
==>HISTORY OF BREAST CA (BR98) [10S] ^ (#910) SYNCHRONOUS BREAST CA (BR98) [11S] ^ (#911) COLON (BR98) [12S] ^
==>(#912) OVARY (BR98) [13S] ^ (#913) UTERUS (BR98) [14S] ^ (#914) PROSTATE (BR98) [15S] ^ (#915) OTHER (BR98)
==>[16S] ^ (#916) HORMONE REPLACEMENT TPY (BR98) [17S] ^ (#917) HORMONE REPLACEMENT YRS (BR98) [18S] ^ (#918)
==>UNKNOWN MAMMOGRAM (BR98) [19S] ^ (#919) UNKNOWN MAMMOGRAM DT (BR98) [20D] ^ (#920) SCREENING MAMMOGRAM
==>(BR98) [21S] ^ (#921) SCREENING MAMMOGRAM DT (BR98) [22D] ^ (#922) DIAGNOSTIC MAMMOGRAM (BR98) [23S] ^
==>(#923) DIAGNOSTIC MAMMOGRAM DT (BR98) [24D] ^ (#924) MAGNIFICATION MAMMOGRAM (BR98) [25S] ^ (#925)
==>MAGNIFICATION MAMM DT (BR98) [26D] ^ (#926) MAMMOGRAM (BR98) [27S] ^ (#927) ULTRASOUND (BR98) [28S] ^
==>(#928) MOST DEFINITIVE MAMM (BR98) [29S] ^ (#929) DATE OF PATHOLOGIC DX (BR98) [30D] ^ (#930) DCSI ALSO
==>PRESENT (BR98) [31F] ^ (#931) ARCHITECTURE PATTERN (BR98) [32S] ^ (#932) NUCLEAR GRADE (BR98) [33S] ^
==>(#933) SKIN INVOLVEMENT (BR98) [34S] ^ (#934) CHEST WALL INVOLVEMENT (BR98) [35S] ^ (#935) PECTORAL
==>INVOLVEMENT (BR98) [36S] ^ (#936) DERMAL/LYMPHATIC INV (BR98) [37S] ^ (#937) DNA INDEX/PLOIDY (BR98) [38S]
==>^ ^ ^ (#940) ANDROGEN RECEPTOR (BR98) [41S] ^ (#941) TYPE OF TEST (BR98) [42S] ^ (#942) SIZE OF DCIS
==>TUMOR (MM) (BR98) [43N] ^ (#943) SENTINEL NODE BIOPSY [44S] ^ (#944) SENTINEL NODES EXAMINED (BR98) [45S] ^
==>(#945) SENTINEL NODES POSITIVE (BR98) [46S] ^ (#946) SENTINEL NODES DETECTED (BR98) [47S] ^ (#947) SPECIMEN
==>RADIOGRAPH (BR98) [48S] ^ (#948) SUBMITTED TO PATHOLOGY (BR98) [49S] ^ (#949) MARGIN DISTANCE (BR98) [50S]
==>^ (#950) RE-EXCISION (BR98) [51S] ^ (#951) MICROSCOPIC STATUS (BR98) [52S] ^ (#952) PRE-RADIATION MAMMOGRAM
==>(BR98) [53S] ^ (#953) SITES IRRADIATED (BR98) [54S] ^ (#954) cGy DOSE TO BREAST (BR98) [55N] ^ (#955)
==>SPECIFIC HORMONE THPY (BR98) [56S] ^ (#956) CHEMOTHERAPY REGIME (BR98) [57S] ^
^ONCO(165.5,D0,CNS1)= (#1200) HANDEDNESS [1S] ^ (#1201) HYPERTENSION [2S] ^ (#1202) MULTIPLE SCLEROSIS (MS) [3S] ^ (#1203)
==>DIABETES [4S] ^ (#1204) CEREBROVASCULAR DISEASE [5S] ^ (#1205) BRAIN [6S] ^ (#1206) BREAST [7S] ^ (#1207)
==>PROSTATE [8S] ^ (#1208) MALIGNANT MELANOMA [9S] ^ (#1209) OTHER SKIN CANCER [10S] ^ (#1210) LEUKEMIA [11S]
==>^ (#1211) COLON OR OTHER GI CANCERS [12S] ^ (#1212) OTHER PERSONAL HISTORY OF CA [13S] ^ (#1213)
==>NEUROFIBROMATOSIS [14S] ^ (#1214) VON HIPPEL-LINDAU DISEASE [15S] ^ (#1215) TUBEROUS SCLEROSIS [16S] ^
==>(#1216) TURCOT SYNDROME [17S] ^ (#1217) LI-FRAUMENI SYNDROME [18S] ^ (#1218) KOWDEN DISEASE [19S] ^ (#1219)
==>NEVOID BASAL CELL CARCINOMA [20S] ^ (#1220) HEADACHE [21S] ^ (#1221) NAUSEA/VOMITING [22S] ^ (#1222) CHANGE
==>IN SENSE OF SMELL/TASTE [23S] ^ (#1223) ALTERED ALERTNESS [24S] ^ (#1224) FATIGUE [25S] ^ (#1225) SPEECH
==>DISTURBANCE [26S] ^ (#1226) PERSONALITY CHANGES [27S] ^ (#1227) DEPRESSION [28S] ^ (#1228) MEMORY LOSS
==>[29S] ^ (#1229) LACK OF CONCENTRATION [30S] ^ (#1230) DOUBLE VISION [31S] ^ (#1231) OTHER VISUAL
==>DISTURBANCE [32S] ^ (#1232) DECREASED HEARING [33S] ^ (#1233) VERTIGO [34S] ^ (#1234) TINNITUS [35S] ^
==>(#1235) NUMBNESS/TINGLING [36S] ^ (#1236) WEAKNESS OR PARALYSIS [37S] ^ (#1237) DIFFICULTY IN COORD/BALANCE
==>[38S] ^ (#1238) GENERALIZED SEIZURE [39S] ^ (#1239) FOCAL SEIZURE [40S] ^ (#1240) BLADDER INCONTINENCE
==>[41S] ^ (#1241) BOWEL INCONTINENCE [42S] ^ (#1242) PAIN (OTHER THAN HEADACHE) [43S] ^ (#1243) WEIGHT CHANGE
==>[44S] ^ (#1244) OTHER SYMPTOMS [45S] ^ (#1245) ALERTNESS [46S] ^ (#1246) SPEECH [47S] ^ (#1247) PERSONALITY
==>[48S] ^ (#1248) MEMORY OR JUDGEMENT [49S] ^ (#1249) VISUAL ACUITY [50S] ^ (#1250) VISUAL FIELDS [51S] ^
==>(#1251) EYE MOVEMENTS (EOM) [52S] ^ (#1252) FACIAL SENSATION [53S] ^ (#1253) FACIAL MOVEMENT [54S] ^
==>(#1254) HEARING [55S] ^ (#1255) GAG REFLEX [56S] ^ (#1256) STERNOCLEIDOMASTOID/SHLD STR [57S] ^ (#1257)
==>ARTICULATION OR ENUNCIATION [58S] ^ (#1258) PAPILLEDEMA [59S] ^ (#1259) TONGUE FASCICULATIONS/ATROPHY [60S]
==>^ (#1260) DECREASE IN SENSATION/ANY SITE [61S] ^ (#1261) CORTICAL SENSORY DEFICIT [62S] ^ (#1262)
==>WEAKNESS/ATROPHY/FASCICULATION [63S] ^ (#1263) ATAXIA OF GAIT [64S] ^ (#1264) TRUNCAL ATAXIA [65S] ^
==>(#1265) DYSMETRIA [66S] ^ (#1266) RAPID ALTERNATING MOVEMENTS [67S] ^ (#1267) FINGER TO FINGER NOSE TESTING
==>[68S] ^ (#1268) HEEL TO KNEE TO SHIN TESTING [69S] ^ (#1269) DEEP TENDON REFLEXES/UPPER EXT [70S] ^ (#1270)
==>DEEP TENDON REFLEXES/LOWER EXT [71S] ^ (#1271) BABINSKI SIGN [72S] ^ (#1272) HOFFMAN REFLEX [73S] ^ (#1273)
==>OTHER ABNORMAL REFLEXES [74S] ^ (#1274) ANGIOGRAPHY [75S] ^ (#1275) COMPUTED TOMOGRAPHY (CT) SCAN [76S] ^
==>(#1276) CT SCAN OF SPINE [77S] ^ (#1277) ELECTROENCEPHALOGRAPHY (EEG) [78S] ^ (#1278) ISOTOPE BRAIN SCAN
==>[79S] ^ (#1279) POSITRON EMISSION TOMOGRAPHY [80S] ^ (#1280) SPECT SCAN [81S] ^ (#1281) MRI OF BRAIN [82S]
==>^ (#1282) MRI OF SPINE [83S] ^ (#1283) FUNCTIONAL MRI [84S] ^ (#1284) MYELOGRAPHY [85S] ^ (#1285) MAGNETIC
==>RES SPECTROSCOPY [86S] ^
^ONCO(165.5,D0,CNS2)= (#1286) FRONTAL LOBE [1S] ^ (#1287) TEMPORAL LOBE [2S] ^ (#1288) PARIETAL LOBE [3S] ^ (#1289) OCCIPITAL
==>LOBE [4S] ^ (#1290) OPTIC NERVES [5S] ^ (#1291) PITUITARY GLAND [6S] ^ (#1292) PINEAL GLAND [7S] ^ (#1293)
==>CEREBELLUM [8S] ^ (#1294) BRAIN STEM [9S] ^ (#1295) SKULL BASE [10S] ^ (#1296) OTHER SKULL [11S] ^ (#1297)
==>SPINAL CORD [12S] ^ (#1298) CEREBRAL SPINAL FLUID (CSF) [13S] ^ (#1299) CRANIAL MENINGES [14S] ^ (#1300)
==>SPINAL MENINGES [15S] ^ (#1301) OTHER TUMOR LOC/INVOLVEMENT [16S] ^ (#1302) LEFT [17S] ^ (#1303) RIGHT
==>[18S] ^ (#1304) MIDLINE [19S] ^ (#1305) NUMBER OF TUMORS [20S] ^ (#1306) DATE OF FIRST SYMPTOMS [21D] ^
==>(#1307) DATE OF PATHOLOGIC DIAGNOSIS [22D] ^ (#1308) WHO HISTOLOGICAL CL [23P:164.9] ^ (#1309) MOLECULAR
==>MARKERS [24S] ^ (#1310) TUMOR SIZE (SOURCE) [25S] ^ (#1311) KARNOFSKY'S RATING PRIOR TO TX [26P:164.17] ^
==>(#1312) PROTOCOL PARTICIPATION (CNS) [27S] ^ (#1313) PROTOCOL PHASE [28S] ^ (#1314) NONE, NO NON-CA DIR
==>SURGERY [29S] ^ (#1315) VENTRICULOSTOMY/EXT VENT DRAIN [30S] ^ (#1316) CSF SHUNT/VENTRICULOPERITONEAL [31S]
==>^ (#1317) CSF SHUNT/3RD VENTRICULOSTOMY [32S] ^ (#1318) CSF SHUNT/OTHER [33S] ^ (#1319) STEREOTACTIC BIOPSY
==>[34S] ^ (#1320) OPEN BRAIN BIOPSY [35S] ^ (#1321) OPEN BX OF SPINCAL CORD TUMOR [36S] ^ (#1322) LAMINECTOMY
==>W/O RESECT/DURA [37S] ^ (#1323) LAMINECTOMY W/O RESECT W DURA [38S] ^ (#1324) SURGERY, NOS [39S] ^ (#1325)
==>UNKNOWN IF SURGERY DONE [40S] ^ (#1326) SURGICAL APPROACH (CNS) [41S] ^ (#1327) EXTENT OF SURGICAL
==>RESECTION [42S] ^ (#1328) SIZE OF RESIDUAL TUMOR [43N] ^ (#1329) SIZE OF RES TUMOR (SOURCE) [44S] ^ (#1330)
==>ANESTHETIC PROBLEM [45S] ^ (#1331) HEMORRHAGE AT OPERATIVE SITE [46S] ^ (#1332) SEIZURE [47S] ^ (#1333)
==>INFECTION(S) [48S] ^ (#1334) DVT (DEEP VENOUS THROMBOSIS) [49S] ^ (#1335) PERSISTENT NEUROL WORSENING [50S]
==>^ (#1336) TOTAL RADIATION DOSE (cGy) [51S] ^ (#1337) TYPE OF EXT BEAM RADIATION [52S] ^ (#1338)
==>INTERSTITIAL RAD/BRACHYTHERAPY [53S] ^ (#1339) STEREOTACTIC RADIOSURGERY [54S] ^ (#1340) SKIN REACTIONS
==>[55S] ^ (#1341) ANOREXIA [56S] ^ (#1342) NAUSEA OR VOMITING [57S] ^ (#1343) FATIGUE [58S] ^ (#1344)
==>NEUROLOGIC WORSENING [59S] ^ (#1345) RADIATION THERAPY [60S] ^ (#1346) PROCARBAZINE [61S] ^ (#1347) CCNU
==>[62S] ^ (#1348) VINCRISTINE [63S] ^ (#1349) HYDROXYUREA [64S] ^ (#1350) BCNU [65S] ^ (#1351) BCNU WAFER
==>IMPLANT [66S] ^ (#1352) VP-16 [67S] ^ (#1353) CARBOPLATIN [68S] ^ (#1354) TEMOZOLOMIDE [69S] ^ (#1355)
==>CPT-11 [70S] ^ (#1356) TAMOXIFEN [71S] ^ (#1357) CYTARABINE (ARA-C) [72S] ^ (#1358) CHEMOTHERAPEUTIC ROUTE
==>[73S] ^ (#1359) HEARING LOSS [74S] ^ (#1360) INFECTION [75S] ^ (#1361) NAUSEA AND VOMITING [76S] ^ (#1362)
==>BLOOD COUNT DROP/BLEEDING [77S] ^ (#1363) PERIPHERAL NEUROPATHY [78S] ^ (#1364) RENAL FAILURE [79S] ^
==>(#1365) PULMONARY TOXICITY [80S] ^ (#1366) OTHER CHEMO COMPLICATIONS [81S] ^ (#1367) KARNOFSKY'S RATING @
==>DIS/TRANS [82P:164.17] ^ (#1368) DATE OF PROGRESSION [83D] ^ (#1369) TYPE OF PROGRESSION [84S] ^ (#1370)
==>RECURRENCE/PROGRESSION DOC [85S] ^ (#1371) KARNOFSKY'S RATING RECURRENCE [86P:164.17] ^ (#1372) TYPE OF 1ST
==>RECURRENCE/CNS [87S] ^ (#1373) PROTOCOL PARTICIPATION (SUBTX) [88S] ^ (#1374) TYPE OF SUBSEQUENT SURGICAL
==>TX [89S] ^ (#1375) TYPE OF SUBSEQUENT RADIATION [90S] ^
^ONCO(165.5,D0,CNS3)= (#1376) PROCARBAZINE (SUB TX) [1S] ^ (#1377) CCNU (SUB TX) [2S] ^ (#1378) VINCRISTINE (SUB TX) [3S] ^
==>(#1379) HYDROXYUREA (SUB TX) [4S] ^ (#1380) METHOTREXATE (SUB TX) [5S] ^ (#1381) CISPLATIN (SUB TX) [6S] ^
==>(#1382) BCNU (SUB TX) [7S] ^ (#1383) BCNU WAFER IMPLANT (SUB TX) [8S] ^ (#1384) VP-16 (SUB TX) [9S] ^
==>(#1385) CARBOPLATIN (SUB TX) [10S] ^ (#1386) TEMOZOLOMIDE (SUB TX) [11S] ^ (#1387) CYCLOPHOSPHAMIDE (SUB
==>TX) [12S] ^ (#1388) CPT-11 (SUB TX) [13S] ^ (#1389) TAMOXIFEN (SUB TX) [14S] ^ (#1390) INTERFERON (SUB TX)
==>[15S] ^ (#1391) CYTARABINE (ARA-C) (SUB TX) [16S] ^ (#1392) OTHER CHEMOTHERAPY (SUB TX) [17S] ^ (#1393)
==>OTHER SUBSEQUENT TREATMENT [18S] ^ (#1394) TUMOR SIZE [19N] ^
^ONCO(165.5,D0,COL1)= (#700) HISTORY OF COLORECTAL CA (FAM) [1S] ^ (#701) HISTORY OF COLORECTAL CA (PT) [2S] ^ (#702) MULTIPLE
==>COLORECTAL PRIMARIES [3S] ^ (#703) HISTORY OF BREAST CA (PT) [4S] ^ (#704) HISTORY OF LUNG CA (PT) [5S] ^
==>(#705) HISTORY OF OVARIAN CA (PT) [6S] ^ (#706) HISTORY OF OVARIAN CARCINOMA [7S] ^ (#707) HISTORY OF
==>STOMACH CA (PT) [8S] ^ (#708) HISTORY OF THYROID CA (PT) [9S] ^ (#709) HISTORY OF UTERUS CA (PT) [10S] ^
==>(#710) PREVIOUS TAH/BSO [11S] ^ (#711) FAMILIAL ADENOMATOUS POLYPS [12S] ^ (#712) HNPCC [13S] ^ (#713)
==>INFLAMMATORY BOWEL DISEASE [14S] ^ (#714) PRIOR POLYPS [15S] ^ (#715) POLYPS [16N] ^ (#716) DURATION OF
==>ANEMIA [17N] ^ (#717) DURATION OF BOWEL OBSTRUCTION [18N] ^ (#718) DURATION OF BOWEL HABIT CHANGE [19N] ^
==>(#719) DURATION OF EMERGENCY PRES-OBS [20N] ^ (#720) DURATION OF JAUNDICE [21N] ^ (#721) DURATION OF
==>MALAISE [22N] ^ (#722) DURATION OF BLOOD IN STOOL [23N] ^ (#723) DURATION OF PAIN (ABDOMINAL) [24N] ^
==>(#724) DURATION OF PAIN (PELVIC) [25N] ^ (#725) DURATION OF RECTAL BLEEDING [26N] ^ (#726) DURATION OF
==>OTHER [27N] ^ (#727) ENDOSCOPIC METHOD [28S] ^ (#728) RADIOGRAPHIC METHOD [29S] ^ (#729) SCREENING DIGITAL
==>RECTAL EXAM [30S] ^ (#730) SCREENING PHYSICAL EXAM METHOD [31S] ^ (#731) OTHER INITIAL METHOD [32S] ^
==>(#732) REASON LEADING TO EVENTUAL DX [33S] ^ (#733) BARIUM ENEMA, DOUBLE CONTRAST [34S] ^ (#734) BARIUM
==>ENEMA, SINGLE CONTRAST [35S] ^ (#735) BARIUM ENEMA, NOS [36S] ^ (#736) BIOPSY OF PRIMARY SITE [37S] ^
==>(#737) BIOPSY OF METASTATIC SITE [38S] ^ (#738) CT SCAN OF LIVER [39S] ^ (#739) CT SCAN OF PRIMARY SITE
==>(COL) [40S] ^ (#740) CARCINOEMBRYONIC ANTIGEN (CEA) [41S] ^ (#741) CHEST ROENTGENOGRAM [42S] ^ (#742)
==>COLONOSCOPY [43S] ^ (#743) DIGITAL RECTAL EXAM [44S] ^ (#744) FLEXIBLE SIGMOIDOSCOPY [45S] ^ (#745)
==>INTRAVENOUS PYELOGRAM (COL) [46S] ^ (#746) SERUM-LIVER FUNCTION TEST [47S] ^ (#747) MRI (COL) [48S] ^
==>(#748) PROCTOSCOPY (RIGID) [49S] ^ (#749) STOOL GUAIAC (OCCULT BLOOD) [50S] ^ (#750) ULTRASOUND, LIVER,
==>ABDOMEN [51S] ^ (#751) ULTRASOUND, ENDORECTAL [52S] ^
^ONCO(165.5,D0,COL2)= (#752) TUMOR LEVEL-ENDOSCOPIC EXAM [1N] ^ (#753) LEVEL OF RECTAL TUMOR [2S] ^ (#754) PROXIMAL MARGIN OF
==>RESECTION [3S] ^ (#755) DISTAL MARGIN OF RESECTION [4S] ^ (#756) RADIAL MARGIN OF RESECTION [5S] ^ (#757)
==>DIST TO CLOSEST MUCOSAL MARGIN [6N] ^ (#758) DIST TO CLOSEST RADIAL MARGIN [7N] ^ (#759) BLOOD VESSEL OR
==>LYMPHATIC INV [8S] ^ (#760) EXTRAMURAL VENOUS INVASION [9S] ^ (#761) PROMINENT LYMPHOID INFILTRATE [10S] ^
==>(#762) PHYS PROVIDING DEF TREATMENT [11S] ^ (#763) ADDITIONAL SURGICAL PROCEDURES [12N] ^ (#764)
==>LAPAROSCOPY USED DURING CDS [13S] ^ (#765) METHOD OF ANASTOMOSIS [14S] ^ (#766) CM FROM ANASTOMOSIS TO
==>DENTATE [15N] ^ (#767) COLOSTOMY [16S] ^ (#768) OOPHORECTOMY [17S] ^ (#769) PATHOLOGICAL STATUS [18S] ^
==>(#770) ABDOMINAL INFECTION [19S] ^ (#771) ABSCESS [20S] ^ (#772) ADMISSION FOR NEUTROPENIA [21S] ^ (#773)
==>ANASTOMOTIC DEHISCENCE [22S] ^ (#774) DEHYDRATION [23S] ^ (#775) DIARRHEA [24S] ^ (#776) EARLY BOWEL
==>OBSTRUCTION [25S] ^ (#777) PERINEAL INFECTION [26S] ^ (#778) PNEUMONIA (COL) [27S] ^ (#779) PROCTITIS [28S]
==>^ (#780) PULMONARY EMBOLISM (COL) [29S] ^ (#781) RADIATION ENTERITIS [30S] ^ (#782) STOMA COMPLICATION
==>[31S] ^ (#783) URINARY TRACT INFECTION [32S] ^ (#784) ENDOCAVITARY RADIATION (ECRT) [33S] ^ (#785)
==>INTRA-OPERATIVE RAD THERAPY [34S] ^ (#786) PRIMARY TUMOR RAD DOSE (cGy) [35N] ^ (#787) NUMBER OF RADIATION
==>TREATMENTS [36N] ^ (#788) ADJUVANT CHEMOTHERAPY (COL) [37S] ^ (#789) 5 FU (FLUOROURACIL) [38S] ^ (#790)
==>LEUCOVORIN [39S] ^ (#791) LEVAMISOLE [40S] ^ (#792) CPT 11 [41S] ^ (#793) OTHER ADJUVANT THERAPY [42S] ^
==>(#794) DURATION OF ADJUVANT THERAPY [43S] ^ (#795) COMPLETED DURATION OF THERAPY [44S] ^ (#796) NUTRITIONAL
==>CONSULTATION [45S] ^ (#797) OCCUPATIONAL THERAPY [46S] ^ (#798) OSTOMY CONSULTATION [47S] ^ (#799)
==>PSYCHOSOCIAL [48S] ^
^ONCO(165.5,D0,CONV)= (#3000) CLASS OF CASE CONVERSION FLAG [1S] ^ (#3001) STATE AT DX CONVERSION FLAG [2S] ^
^ONCO(165.5,D0,CS)= (#29.1) TUMOR SIZE/EXT EVAL (CS) [1F] ^ (#32.1) LYMPH NODES EVAL (CS) [2F] ^ (#34.3) METS AT DX (CS) [3F] ^
==>(#34.4) METS EVAL (CS) [4F] ^ (#44.1) SSF1 [5F] ^ (#44.2) SSF2 [6F] ^ (#44.3) SSF3 [7F] ^ (#44.4) SSF4 [8F] ^
==>(#44.5) SSF5 [9F] ^ (#44.6) SSF6 [10F] ^ (#30.2) EXTENSION (CS) [11F] ^ (#31.1) LYMPH NODES (CS) [12F] ^
^ONCO(165.5,D0,CS1)= (#160) DERIVED AJCC-6 T [1F] ^ (#161) DERIVED AJCC-6 T DESCRIPTOR [2S] ^ (#162) DERIVED AJCC-6 N [3F] ^
==>(#163) DERIVED AJCC-6 N DESCRIPTOR [4S] ^ (#164) DERIVED AJCC-6 M [5F] ^ (#165) DERIVED AJCC-6 M DESCRIPTOR
==>[6S] ^ (#166) DERIVED AJCC-6 STAGE GROUP [7F] ^ (#167) DERIVED SS1977 [8S] ^ (#168) DERIVED SS2000 [9S] ^
==>(#29.2) TUMOR SIZE (CS) [10F] ^ (#169) CS VERSION DERIVED [11F] ^ (#169.1) CS VERSION INPUT ORIGINAL [12F] ^
==>(#160.7) DERIVED AJCC-7 T [13F] ^ (#161.7) DERIVED AJCC-7 T DESCRIPTOR [14S] ^ (#162.7) DERIVED AJCC-7 N
==>[15F] ^ (#163.7) DERIVED AJCC-7 N DESCRIPTOR [16S] ^ (#164.7) DERIVED AJCC-7 M [17F] ^ (#165.7) DERIVED
==>AJCC-7 M DESCRIPTOR [18S] ^ (#166.7) DERIVED AJCC-7 STAGE GROUP [19F] ^ (#34.31) METS AT DX-BONE [20S] ^
==>(#34.32) METS AT DX-BRAIN [21S] ^ (#34.33) METS AT DX-LIVER [22S] ^ (#34.34) METS AT DX-LUNG [23S] ^
==>(#34.35) METS AT DX-DISTANT LN [24S] ^ (#34.36) METS AT DX-OTHER [25S] ^
^ONCO(165.5,D0,CS2)= (#44.7) SSF7 [1F] ^ (#44.8) SSF8 [2F] ^ (#44.9) SSF9 [3F] ^ (#44.101) SSF10 [4F] ^ (#44.11) SSF11 [5F] ^
==>(#44.12) SSF12 [6F] ^ (#44.13) SSF13 [7F] ^ (#44.14) SSF14 [8F] ^ (#44.15) SSF15 [9F] ^ (#44.16) SSF16 [10F]
==>^ (#44.17) SSF17 [11F] ^ (#44.18) SSF18 [12F] ^ (#44.19) SSF19 [13F] ^ (#44.201) SSF20 [14F] ^ (#44.21)
==>SSF21 [15F] ^ (#44.22) SSF22 [16F] ^ (#44.23) SSF23 [17F] ^ (#44.24) SSF24 [18F] ^ (#44.25) SSF25 [19F] ^
^ONCO(165.5,D0,CS3)= (#240) CS SCHEMA DISCRIMINATOR [1F] ^ (#247) CS REVIEW REQUIRED [2S] ^ (#283) CS FIELD NEEDING REVIEW [3F] ^
^ONCO(165.5,D0,DIV)= (#2000) DIVISION [1P:4] ^
^ONCO(165.5,D0,EDITS)= (#197) EDITS CHECKSUM [1F] ^ (#197.1) CHECKSUM VERSION [2F] ^ (#282) VACCR EXTRACT INDICATOR [3S] ^
^ONCO(165.5,D0,EOD)= (#1772) EOD PRIMARY TUMOR [1N] ^ (#1774) EOD REGIONAL NODES [2N] ^ (#1776) EOD METS [3N] ^ (#1764) SUMMARY
==>STAGE 2018 [4S] ^ (#245.1) NEOADJUVANT THERAPY [5S] ^ (#245.2) NEOADJUVANT THERAPY-CLIN RESP [6S] ^ (#245.3)
==>NEOADJUVANT THERAPY-TX EFFECT [7N] ^
^ONCO(165.5,D0,GAS1)= (#1500) GAS PRIOR EXPOSURE TO RAD [1S] ^ (#1501) GAS ALCOHOL COMSUMPTION [2F] ^ (#1502) GAS MENOPAUSAL
==>STATUS/HOR TX [3S] ^ (#1503) GAS H2 BLOCKER/PROTON PUMP [4S] ^ (#1504) GAS FAMILY HIST OF GASTRIC CA [5S] ^
==>(#1505) GAS H-PYLORI INFECTION [6S] ^ (#1506) GAS DUODENAL ULCER [7S] ^ (#1507) GAS GASTRIC ULCER [8S] ^
==>(#1508) GAS HEARTBURN (BENIGN COND) [9S] ^ (#1509) GAS PERNICIOUS ANEMIA [10S] ^ (#1510) GAS POLYPS OF
==>STOMACH [11S] ^ (#1511) GAS POLYPOSIS OF BOWEL [12S] ^ (#1512) GAS BARRET'S ESOPHAGUS [13S] ^ (#1513) GAS
==>ATROPHIC GASTRITIS [14S] ^ (#1514) GAS GASTRIC METAPLASIA [15S] ^ (#1515) GAS ANTIBIOTICS [16S] ^ (#1516)
==>GAS PROTON PUMP INHIBITORS [17S] ^ (#1517) GAS H2 BLOCKERS [18S] ^ (#1518) GAS BISMUTH COMPOUNDS [19S] ^
==>(#1519) GAS PRIOR INTRA-ABDOMINAL SURG [20S] ^ (#1520) GAS YEAR OF GASTRIC RESECTION [21F] ^ (#1521) GAS
==>PERFORMANCE STATUS AT DX [22S] ^ (#1522) GAS HEARTBURN (SYMPTOMS) [23S] ^ (#1523) GAS FEVER/NIGHT SWEATS
==>[24S] ^ (#1524) GAS ACUTE HEMATEMESIS [25S] ^ (#1525) GAS TRANSFUSIONS FOR BLD LOSS [26S] ^ (#1526) GAS
==>MELENA [27S] ^ (#1527) GAS PAIN [28S] ^ (#1528) GAS EARLY SATIETY [29S] ^ (#1529) GAS CT SCAN OF ABDOMEN
==>[30S] ^ (#1530) GAS CT SCAN OF CHEST [31S] ^ (#1531) GAS CT PELVIS [32S] ^ (#1532) GAS CHEST X-RAY [33S] ^
==>(#1533) GAS GALLIUM SCAN [34S] ^ (#1534) GAS BIPEDAL LYMPHANGIOGRAM [35S] ^ (#1535) GAS MRI [36S] ^ (#1536)
==>GAS PET SCAN [37S] ^ (#1537) GAS LAPAROSCOPY [38S] ^ (#1538) GAS EUS [39S] ^ (#1539) GAS PERITONEAL LAVAGE
==>[40S] ^ (#1540) GAS LDH (IU/L) [41N] ^ (#1541) GAS CEA (ng/ml) [42N] ^ (#1542) GAS CA125 (U/ml) [43N] ^
==>(#1543) GAS BETA2 MICROGLOBULIN [44N] ^ (#1544) GAS URINARY 5-HIAA (mg/24hr) [45N] ^ (#1545) GAS
==>CLINICAL/VISUAL EXAM [46S] ^ (#1545.1) GAS BIOPSY [47S] ^ (#1546) GAS GASTRO-ESOPHAGEAL JUNCTION [48S] ^
==>(#1547) GAS STOMACH [49S] ^ (#1547.1) GAS LIVER [50S] ^ (#1547.2) GAS EXTRA-ABDOMINAL [51S] ^ (#1547.3) GAS
==>LYMPH NODES [52S] ^ (#1547.4) GAS PERITONEUM [53S] ^ (#1548) GAS DATE OF FIRST TISSUE DX [54D] ^ (#1549)
==>GAS LAUREN'S CLASSIFICATION [55S] ^ (#1550) GAS GOSEKI'S CLASSIFICATION [56S] ^ (#1551) GAS GASTRIN [57S] ^
==>(#1551.1) GAS 5-HIAA [58S] ^ (#1551.2) GAS CEA [59S] ^ (#1551.3) GAS CA125 [60S] ^ (#1551.4) GAS OTHER
==>MOLECULAR MARKER [61S] ^ (#1552) GAS MITOTIC RATE [62S] ^ (#1553) GAS TUMOR NECROSIS [63S] ^ (#1554) GAS
==>FLOW CYTOMETRY/FRESH TISS [64S] ^ (#1554.1) GAS IMMUNOHISTOCHEM/FROZEN TIS [65S] ^ (#1554.2) GAS
==>IMMUNOHISTOCHEM/PARAFFIN [66S] ^ (#1554.3) GAS MOLECULAR GENETICS [67S] ^ (#1554.4) GAS POLYMERASE CHAIN
==>REACTION [68S] ^ (#1554.5) GAS SOUTHERN BLOT TECHNIQUE [69S] ^ (#1555) GAS ANN ARBOR STAGING [70S] ^
==>(#1556) GAS ADHERENCE OF RESECTED PRIM [71S] ^ (#1557) GAS MARGIN STAT OF RESECT PRIM [72S] ^ (#1558) GAS
==>PROXIMAL MARGIN [73F] ^ (#1558.1) GAS DISTAL MARGIN [74F] ^
^ONCO(165.5,D0,GAS2)= (#1559) GAS SPLEEN [1S] ^ (#1559.1) GAS TRANSVERSE COLON [2S] ^ (#1559.2) GAS LIVER [3S] ^ (#1559.3) GAS
==>DIAPHRAGM [4S] ^ (#1559.4) GAS PANCREAS [5S] ^ (#1559.5) GAS ABDOMINAL WALL [6S] ^ (#1559.6) GAS ADRENAL
==>GLAND [7S] ^ (#1559.7) GAS KIDNEY [8S] ^ (#1559.8) GAS SMALL INTESTINE [9S] ^ (#1559.9) GAS RETROPERITONEUM
==>[10S] ^ (#1560) GAS PERIGASTRIC LYMPH NODES [11S] ^ (#1560.1) GAS COMMON HEPATIC LYMPH NODES [12S] ^
==>(#1560.2) GAS CELIAC LYMPH NODES [13S] ^ (#1560.3) GAS SPLENIC LYMPH NODES [14S] ^ (#1560.4) GAS OTHER
==>INTRA-ABDOMINAL NDES [15S] ^ (#1561) GAS GROSSLY INVOLVED REG LN [16S] ^ (#1562) GAS HCT VAL BEFORE
==>TRANSFUSION [17N] ^ (#1563) GAS TOTAL OPERATIVE BLOOD REPL [18F] ^ (#1564) GAS INTRA/PERI-OPERATIVE DEATH
==>[19S] ^ (#1565) GAS ANASTOMATIC LEAK [20S] ^ (#1565.1) GAS STUMP LEAK [21S] ^ (#1565.2) GAS BLEEDING [22S]
==>^ (#1565.3) GAS WOUND INFECTION [23S] ^ (#1565.4) GAS SEPSIS [24S] ^ (#1565.5) GAS PANCREATITIS [25S] ^
==>(#1565.6) GAS DEAD BOWEL [26S] ^ (#1565.7) GAS OTHER COMPLICATIONS [27S] ^ (#1566) GAS DATE OF SURGICAL
==>DISCHARGE [28D] ^ (#1567) GAS INTRA-OPERATIVE RADIATION [29F] ^ (#1568) GAS CONCURRENT CHEMOTHERAPY [30S] ^
==>(#1569) GAS INTRAPERITONEAL CMX [31S] ^ (#1570) GAS ADMIN OF INTERFERON [32S] ^ (#1571) GAS CO-MORBID
==>CONDITION 1 [33P:80] ^ (#1571.1) GAS CO-MORBID CONDITION 2 [34P:80] ^ (#1571.2) GAS CO-MORBID CONDITION 3
==>[35P:80] ^ (#1571.3) GAS CO-MORBID CONDITION 4 [36P:80] ^ (#1571.4) GAS CO-MORBID CONDITION 5 [37P:80] ^
==>(#1571.5) GAS CO-MORBID CONDITION 6 [38P:80] ^ (#1572) GAS DURATION OF TOBACCO USE [39F] ^ (#1573) GAS
==>PERSONAL HIST OTH MALIG [40P:164] ^ (#1574) GAS WEIGHT LOSS [41S] ^ (#1575) GAS BOOST DOSE (cGy) [42F] ^
==>(#1576) GAS CHEMOTHERAPEUTIC AGENT #1 [43P:164.18] ^ (#1576.1) GAS CHEMOTHERAPEUTIC AGENT #2 [44P:164.18] ^
==>(#1576.2) GAS CHEMOTHERAPEUTIC AGENT #3 [45P:164.18] ^ (#1577) GAS CHEMOTHERAPEUTIC TOXICITY [46S] ^
==>(#1578) GAS CHEMOTHERAPY/SURG SEQUENCE [47S] ^ (#1579) GAS COMPLICATION #1 [48P:80] ^ (#1579.1) GAS
==>COMPLICATION #2 [49P:80] ^ (#1579.2) GAS COMPLICATION #3 [50P:80] ^ (#1579.3) GAS COMPLICATION #4 [51P:80]
==>^ (#1579.4) GAS COMPLICATION #5 [52P:80] ^
^ONCO(165.5,D0,HEP1)= (#1000) ORAL CONTRACEPTIVES [1S] ^ (#1001) ESTROGEN REPLACEMENT [2S] ^ (#1002) TAMOXIFEN [3S] ^ (#1003)
==>OTHER HORMONES [4S] ^ (#1004) ASCITES [5S] ^ (#1005) CIRRHOSIS [6S] ^ (#1006) CHILD'S CLASS A [7S] ^
==>(#1007) CHILD'S CLASS B [8S] ^ (#1008) CHILD'S CLASS C [9S] ^ (#1009) HEPATITIS B [10S] ^ (#1010) HEPATITIS
==>C [11S] ^ (#1011) HEMOCHROMATOSIS [12S] ^ (#1012) ALCOHOL CONSUMPTION [13F] ^ (#1013) AFP (IU/ml) [14F] ^
==>(#1014) CEA (mg/ml) [15F] ^ (#1015) CA19.9 (U/ml) [16F] ^ (#1016) PROTIME (sec) [17F] ^ (#1017) BILIRUBIN
==>(mg/ml) [18F] ^ (#1018) ALBUMIN (g/dl) [19F] ^ (#1019) LDH (U/I) [20F] ^ (#1020) CT ARTERIAL PORT-PERFORMED
==>[21S] ^ (#1021) CT ARTERIAL PORT-CIRRHOSIS [22S] ^ (#1022) CT ARTERIAL PORT-VASCULAR INV [23S] ^ (#1023) CT
==>ARTERIAL PORT-BILOBAR DIS [24S] ^ (#1024) CT ARTERIAL PORT-LYMPH NODES [25S] ^ (#1025) CT ARTERIAL
==>PORT-SIZE OF TUMOR [26F] ^ (#1026) CT ARTERIAL PORT-NUM 0F TUMORS [27F] ^ (#1027) SPIRAL CT-PERFORMED [28S]
==>^ (#1028) SPIRAL CT-CIRRHOSIS [29S] ^ (#1029) SPIRAL CT-VASCULAR INV [30S] ^ (#1030) SPIRAL CT-BILOBAR DIS
==>[31S] ^ (#1031) SPIRAL CT-LYMPH NODES [32S] ^ (#1032) SPIRAL CT-SIZE OF TUMOR [33F] ^ (#1033) SPIRAL CT-NUM
==>OF TUMORS [34F] ^ (#1034) INCREMENTAL CT-PERFORMED [35S] ^ (#1035) INCREMENTAL CT-CIRRHOSIS [36S] ^ (#1036)
==>INCREMENTAL CT-VASCULAR INV [37S] ^ (#1037) INCREMENTAL CT-BILOBAR DIS [38S] ^ (#1038) INCREMENTAL CT-LYMPH
==>NODES [39S] ^ (#1039) INCREMENTAL CT-SIZE OF TUMOR [40F] ^ (#1040) INCREMENTAL CT-NUM 0F TUMORS [41F] ^
==>(#1041) ULTRASOUND-PERFORMED [42S] ^ (#1042) ULTRASOUND-CIRRHOSIS [43S] ^ (#1043) ULTRASOUND-VASCULAR INV
==>[44S] ^ (#1044) ULTRASOUND-BILOBAR DIS [45S] ^ (#1045) ULTRASOUND-LYMPH NODES [46S] ^ (#1046)
==>ULTRASOUND-SIZE OF TUMOR [47F] ^ (#1047) ULTRASOUND-NUM 0F TUMORS [48F] ^ (#1048) MRI-PERFORMED [49S] ^
==>(#1049) MRI-CIRRHOSIS [50S] ^ (#1050) MRI-VASCULAR INV [51S] ^ (#1051) MRI-BILOBAR DIS [52S] ^ (#1052)
==>MRI-LYMPH NODES [53S] ^ (#1053) MRI-SIZE OF TUMOR [54F] ^ (#1054) MRI-NUM 0F TUMORS [55F] ^ (#1055)
==>DEFINITIVE DIAGNOSIS [56S] ^ (#1056) RADIO-FREQUENCY DESTRUCTION [57S] ^ (#1057) ABLATION & RESECTION [58S]
==>^ (#1058) DISTANCE TO CLOSEST MARGIN [59S] ^ (#1059) ABLATION [60S] ^ (#1060) RESECTION [61S] ^ (#1061)
==>CISPLATIN [62S] ^ (#1062) FUDR [63S] ^ (#1063) 5-FU [64S] ^ (#1064) FU & LEUCOVORIN [65S] ^ (#1065)
==>IRINOTECAN (CPT-11) [66S] ^ (#1066) MITOMYCIN C [67S] ^ (#1067) OXALIPLATIN [68S] ^ (#1068) GEMCITABINE
==>[69S] ^ (#1069) ROUTE CHEMO ADMIN [70S] ^ (#1070) CHEMOTHERAPY/SURGERY SEQUENCE [71S] ^ (#1071) ARTERIAL
==>EMBOLIZATION [72S] ^ (#1072) DEATH W/I 30 DAYS START TX [73S] ^
^ONCO(165.5,D0,LUN1)= (#1400) LNG CO-MORBID CONDITION 1 [1P:80] ^ (#1400.1) LNG CO-MORBID CONDITION 2 [2P:80] ^ (#1400.2) LNG
==>CO-MORBID CONDITION 3 [3P:80] ^ (#1400.3) LNG CO-MORBID CONDITION 4 [4P:80] ^ (#1400.4) LNG CO-MORBID
==>CONDITION 5 [5P:80] ^ (#1400.5) LNG CO-MORBID CONDITION 6 [6P:80] ^ (#1401) LNG DURATION OF TOBACCO USE
==>[7F] ^ (#1402) LNG DATE OF FIRST TISSUE DX [8D] ^ (#1403) LNG PERSONAL HIST OTH MALIG [9P:164] ^ (#1404)
==>LNG COUGH [10S] ^ (#1404.1) LNG SHORTNESS OF BREATH [11S] ^ (#1404.2) LNG WEIGHT LOSS [12S] ^ (#1404.3) LNG
==>HEMOPTYSIS [13S] ^ (#1404.4) LNG PALPABLE LYMPH NODES [14S] ^ (#1405) LNG CHEST X-RAY [15S] ^ (#1405.1) LNG
==>CT SCAN [16S] ^ (#1405.2) LNG BRONCHOSCOPY [17S] ^ (#1406) LNG HISTORY AND PHYSICAL [18S] ^ (#1406.1) LNG
==>BRONCHOSCOPY PRE-THERAPY [19S] ^ (#1406.2) LNG FNAB [20S] ^ (#1406.3) LNG MEDIASTINOSCOPY [21S] ^ (#1406.4)
==>LNG THOROCOTOMY/OPEN BIOPSY [22S] ^ (#1406.5) LNG VATS [23S] ^ (#1407) LNG FVC [24N] ^ (#1407.1) LNG FEV
==>[25N] ^ (#1408) LNG LIVER FUNCTION TESTS [26S] ^ (#1409) LNG BONE SCAN [27S] ^ (#1409.1) LNG EMPHYSEMA
==>(BONE SCAN) [28S] ^ (#1409.2) LNG VASCULAR INV (BONE SCAN) [29S] ^ (#1409.3) LNG MEDIASTINAL LN (BONE SCAN)
==>[30S] ^ (#1409.4) LNG TUMOR SIZE (BONE SCAN) [31F] ^ (#1409.5) LNG NUM OF TUMORS (BONE SCAN) [32F] ^
==>(#1409.6) LNG METASTASIS (BONE SCAN) [33S] ^ (#1410) LNG CT SCAN OF CHEST [34S] ^ (#1410.1) LNG EMPHYSEMA
==>(CHEST CT) [35S] ^ (#1410.2) LNG VASCULAR INV (CHEST CT) [36S] ^ (#1410.3) LNG MEDIASTINAL LN (CHEST CT)
==>[37S] ^ (#1410.4) LNG TUMOR SIZE (CHEST CT) [38F] ^ (#1410.5) LNG NUM OF TUMORS (CHEST CT) [39F] ^
==>(#1410.6) LNG METASTASIS (CHEST CT) [40S] ^ (#1411) LNG CT SCAN OF BRAIN [41S] ^ (#1411.1) LNG EMPHYSEMA
==>(BRAIN CT) [42S] ^ (#1411.2) LNG VASCULAR INV (BRAIN CT) [43S] ^ (#1411.3) LNG MEDIASTINAL LN (BRAIN CT)
==>[44S] ^ (#1411.4) LNG TUMOR SIZE (BRAIN CT) [45F] ^ (#1411.5) LNG NUM OF TUMORS (BRAIN CT) [46F] ^
==>(#1411.6) LNG METASTASIS (BRAIN CT) [47S] ^ (#1412) LNG MRI SCAN OF CHEST [48S] ^ (#1412.1) LNG EMPHYSEMA
==>(CHEST MRI) [49S] ^ (#1412.2) LNG VASCULAR INV (CHEST MRI) [50S] ^ (#1412.3) LNG MEDIASTINAL LN (CHEST MRI)
==>[51S] ^ (#1412.4) LNG TUMOR SIZE (CHEST MRI) [52F] ^ (#1412.5) LNG NUM OF TUMORS (CHEST MRI) [53F] ^
==>(#1412.6) LNG METASTASIS (CHEST MRI) [54S] ^ (#1413) LNG MRI SCAN OF BRAIN [55S] ^ (#1413.1) LNG EMPHYSEMA
==>(BRAIN MRI) [56S] ^ (#1413.2) LNG VASCULAR INV (BRAIN MRI) [57S] ^ (#1413.3) LNG MEDIASTINAL LN (BRAIN MRI)
==>[58S] ^ (#1413.4) LNG TUMOR SIZE (BRAIN MRI) [59F] ^ (#1413.5) LNG NUM OF TUMORS (BRAIN MRI) [60F] ^
==>(#1413.6) LNG METASTASIS (BRAIN MRI) [61S] ^ (#1414) LNG PET SCAN [62S] ^ (#1414.1) LNG EMPHYSEMA (PET
==>SCAN) [63S] ^ (#1414.2) LNG VASCULAR INV (PET SCAN) [64S] ^ (#1414.3) LNG MEDIASTINAL LN (PET SCAN) [65S] ^
==>(#1414.4) LNG TUMOR SIZE (PET SCAN) [66F] ^ (#1414.5) LNG NUM OF TUMORS (PET SCAN) [67F] ^ (#1414.6) LNG
==>METASTASIS (PET SCAN) [68S] ^ (#1415) LNG X-RAY OF CHEST [69S] ^ (#1415.1) LNG EMPHYSEMA (CHEST XRAY) [70S]
==>^ (#1415.2) LNG VASCULAR INV (CHEST XRAY) [71S] ^ (#1415.3) LNG MEDIASTINAL (CHEST XRAY) [72S] ^ (#1415.4)
==>LNG TUMOR SIZE (CHEST XRAY) [73F] ^ (#1415.5) LNG NUM OF TUMORS (CHEST XRAY) [74F] ^ (#1415.6) LNG
==>METASTASIS (CHEST XRAY) [75S] ^ (#1400.6) LNG CO-MORBID CONDITION Y/N [76S] ^
^ONCO(165.5,D0,LUN2)= (#1416) LNG HIGH MEDIASTINAL (PRE-OP) [1S] ^ (#1416.1) LNG UPPER PARATRACH (PRE-OP) [2S] ^ (#1416.2) LNG
==>PREVASC/RETRO (PRE-OP) [3S] ^ (#1416.3) LNG LOWER PARATRACH (PRE-OP) [4S] ^ (#1416.4) LNG SUBAORTIC
==>(PRE-OP) [5S] ^ (#1416.5) LNG PARAORTIC (PRE-OP) [6S] ^ (#1416.6) LNG SUBCARINAL (PRE-OP) [7S] ^ (#1416.7)
==>LNG PARAESOPHAGEAL (PRE-OP) [8S] ^ (#1416.8) LNG PULMONARY LIG (PRE-OP) [9S] ^ (#1417) LNG FROZEN SECTION
==>[10S] ^ (#1418) LNG VASCULAR INVASION [11S] ^ (#1418.1) LNG LYMPHATICS INVASION [12S] ^ (#1418.2) LNG
==>PLEURA INVASION [13S] ^ (#1418.3) LNG CHEST WALL INVASION [14S] ^ (#1418.4) LNG OTHER INVASION [15S] ^
==>(#1419) LNG HIGH MEDIASTINAL (SCOPE) [16S] ^ (#1419.1) LNG UPPER PARATRACHEAL (SCOPE) [17S] ^ (#1419.2) LNG
==>PREVASC/RETROTRACH (SCOPE) [18S] ^ (#1419.3) LNG LOWER PARATRACHEAL (SCOPE) [19S] ^ (#1419.4) LNG SUBAORTIC
==>(SCOPE) [20S] ^ (#1419.5) LNG PARAORTIC (SCOPE) [21S] ^ (#1419.6) LNG SUBCARINAL (SCOPE) [22S] ^ (#1419.7)
==>LNG PARAESOPHAGEAL (SCOPE) [23S] ^ (#1419.8) LNG PULMONARY LIGAMENT (SCOPE) [24S] ^ (#1420) LNG
==>PERI-OPERATIVE BLOOD REP [25F] ^ (#1421) LNG PERI-OPERATIVE DEATH [26S] ^ (#1422) LNG BOOST DOSE (cGy)
==>[27F] ^ (#1423) CHEMOTHERAPEUTIC AGENT #1 [28P:164.18] ^ (#1423.1) CHEMOTHERAPEUTIC AGENT #2 [29P:164.18] ^
==>(#1423.2) CHEMOTHERAPEUTIC AGENT #3 [30P:164.18] ^ (#1424) LNG CHEMOTHERAPEUTIC TOXICITY [31S] ^ (#1425)
==>LNG CHEMOTHERAPY/SURG SEQUENCE [32S] ^ (#1426) LNG COMPLICATION #1 [33P:80] ^ (#1426.1) LNG COMPLICATION #2
==>[34P:80] ^ (#1426.2) LNG COMPLICATION #3 [35P:80] ^ (#1426.3) LNG COMPLICATION #4 [36P:80] ^ (#1426.4) LNG
==>COMPLICATION #5 [37P:80] ^ (#1427) LNG CASE ABSTRACTOR INITIALS [38F] ^ (#1428) LNG DATE CASE WAS
==>ABSTRACTED [39D] ^ (#1426.5) LNG TREATMENT COMPLICATION Y/N [40S] ^ (#1429) LNG PROXIMAL MARGIN [41F] ^
==>(#1429.1) LNG DISTAL MARGIN [42F] ^ (#1430) LNG HCT VAL BEFORE TRANSFUSION [43N] ^ (#1423.3)
==>CHEMOTHERAPEUTIC AGENT #4 [44P:164.18] ^ (#1423.4) CHEMOTHERAPEUTIC AGENT #5 [45P:164.18] ^
^ONCO(165.5,D0,MEL1)= (#1100) HISTORY OF MELANOMA (PT) [1S] ^ (#1101) HISTORY OF OTHER CANCER (PT) [2S] ^ (#1102) FIRST SITE CODE
==>[3P:164] ^ (#1103) FIRST SITE DIAGNOSIS DATE [4D] ^ (#1104) SECOND SITE CODE [5P:164] ^ (#1105) SECOND SITE
==>DIAGNOSIS DATE [6D] ^ (#1106) PREGNANCY AT INITIAL DIAGNOSIS [7S] ^ (#1107) EXOGENOUS HORMONES [8S] ^
==>(#1108) DISEASE PRESENTATION LOCATION [9S] ^ (#1109) TYPE OF BIOPSY [10S] ^ (#1110) EXTRANODAL EXTENSION
==>[11S] ^ (#1111) MICROSATELLITOSIS [12S] ^ (#1112) NUMBER OF SATELLITE NODULES [13F] ^ (#1113) LOCATION OF
==>IN-TRANSIT NODULES [14S] ^ (#1114) BRESLOW'S THICKNESS [15F] ^ (#1115) CLARK'S LEVEL OF INVASION [16S] ^
==>(#1116) ANGIOLYMPHATIC INVASION [17S] ^ (#1117) PERINEURAL INVASION [18S] ^ (#1118) ULCERATION [19S] ^
==>(#1119) CLINICALLY AMELANOTIC [20S] ^ (#1120) MARGIN DISTANCE (MEL) [21F] ^ (#1121) SURGICAL CLOSURE [22S]
==>^ (#1122) PRE-OP LYMPHOSCINTIGRAPHY [23S] ^ (#1123) SENTINEL NODES DETECTED BY [24S] ^ (#1124) SENTINEL
==>NODES EXAMINED (MEL) [25S] ^ (#1125) SENTINEL NODES POSITIVE (MEL) [26S] ^ (#1126) METHOD OF PATHOLOGIC
==>EXAM [27S] ^ (#1127) LYMPH NODE DISSECTION [28S] ^ (#1128) NUMBER OF BASINS DISSECTED [29S] ^ (#1129)
==>NUMBER OF BASINS POSITIVE [30S] ^ (#1130) INTRAVENOUS THERAPY [31S] ^ (#1131) GENE THERAPY [32S] ^ (#1132)
==>SIZE OF TUMOR (MELANOMA) [33N] ^
^ONCO(165.5,D0,NCR18)= (#7000) STATE AT DX GEOCODE 1970/80/90 [1P:5] ^ (#7001) STATE AT DX GEOCODE 2010 [2P:5] ^ (#7002) BEHAVIOR
==>(73-91) ICD-O-1 [3N] ^ (#7003) GRADE (73-91) ICD-O-1 [4N] ^ (#7004) RUCA 2000 [5S] ^ (#7005) RUCA 2010
==>[6S] ^ (#7006) URIC 2000 [7S] ^ (#7007) URIC 2010 [8S] ^ (#7008) DERIVED EOD 2018 T [9F] ^ (#7009) DERIVED
==>EOD 2018 N [10F] ^ (#7010) DERIVED EOD 2018 M [11F] ^ (#7011) DERIVED EOD 2018 STAGE GROUP [12F] ^ (#7012)
==>DERIVED SUMMARY STAGE 2018 [13S] ^ (#7013) DATE REGIONAL LN DISSECTION [14D] ^ (#7014) DATE REG LN
==>DISSECTION FLAG [15S] ^ (#7015) SENTINEL LYMPH NODES POSITIVE [16F] ^ (#7016) SENTINEL LYMPH NODES
==>EXAMINED [17F] ^ (#7017) DATE OF SENTINEL LN BIOPSY [18D] ^ (#7018) DATE OF SENTINEL LN BIOPSY FLG [19S] ^
==>(#7019) NPCR DERIVED AJCC8 CLN STG GRP [20F] ^ (#7020) NPCR DERIVED AJCC8 PTH STG GRP [21F] ^ (#7021) NPCR
==>DERIVED AJCC8 PT STG GRP [22F] ^ (#7022) NPCR SPECIFIC FIELD [23F] ^ (#7023) STATE AT DX GEOCODE 2000
==>[24P:5] ^
^ONCO(165.5,D0,NCR18B)= (#7024) NUMBER OF PHASES RAD TX [1S] ^ (#7025) RADIATION TREATMENT DISC EARLY [2S] ^ (#7026) TOTAL DOSE
==>[3F] ^ (#7027) OVER-RIDE TNM STAGE [4S] ^ (#7028) OVER-RIDE TNM TIS [5S] ^ (#7029) OVER-RIDE TNM 3 [6S] ^
==>(#7030) OVER-RIDE NAME/SEX [7S] ^ (#7031) HISTOLOGY (73-91) ICD-O-1 [8N] ^ (#7032) RQRS NCDB SUBMISSION
==>FLAG [9S] ^ (#7033) COC ACCREDITED FLAG [10S] ^ (#7034) VITAL STATUS RECODE [11S] ^ ^ ^ (#7037) RECORD
==>NUMBER RECODE [14N] ^ (#7038) SEER CAUSE SPECIFIC COD [15S] ^ (#7039) SEER OTHER COD [16S] ^ (#7040)
==>MEDICARE BENEFICIARY ID [17F] ^
^ONCO(165.5,D0,NCR21)= (#3943) NCDB-SARSCOV2-TEST [1S] ^ (#3944) NCDB-SARSCOV2-POSITIVE [2S] ^ (#3945) NCDB-SARSCOV2-POSITIVE
==>DATE [3D] ^ (#3946) NCDB-COVID19-TX IMPACT [4S] ^
^ONCO(165.5,D0,NHL1)= (#800) HISTORY OF LEUKEMIA (FAM) [1S] ^ (#801) HISTORY OF NON-HODGKIN'S LYMPH [2S] ^ (#802) HISTORY OF
==>HODGKIN'S LYMPHOMA [3S] ^ (#803) 1ST PRIMARY SITE [4P:164] ^ (#804) 1ST PRIMARY HISTOLOGY [5P:164.1] ^
==>(#805) 2ND PRIMARY SITE [6P:164] ^ (#806) 2ND PRIMARY HISTOLOGY [7P:164.1] ^ (#807) ORGAN TRANSPLANT [8S] ^
==>(#808) HIV POSITIVE [9S] ^ (#809) CROHN'S DISEASE [10S] ^ (#810) HASHIMOTO'S THYROIDITIS [11S] ^ (#811)
==>SYSTEMIC LUPUS ERYTHEMATOSUS [12S] ^ (#812) RHEUMATOID ARTHRITIS [13S] ^ (#813) PNEUMOCYSTIS CARINII [14S]
==>^ (#814) CMV INFECTION [15S] ^ (#815) TUBERCULOSIS [16S] ^ (#816) MYCOBACTERIUM AVIUM [17S] ^ (#817) OTHER
==>PARASITIC INFECTIONS [18S] ^ (#818) OTHER CONGENITAL DISEASES [19S] ^ (#819) OPPORTUNISTIC DISEASE [20S] ^
==>(#820) PREVIOUS CHEMOTHERAPY [21S] ^ (#821) PREVIOUS RADIATION THERAPY [22S] ^ (#822) AIDS RISK CATEGORY
==>[23N] ^ (#823) CT SCAN OF BRAIN [24S] ^ (#824) CT SCAN OF ABDOMEN/PELVIS [25S] ^ (#825) MRI OF BRAIN [26S]
==>^ (#826) MRI OF CHEST [27S] ^ (#827) MRI OF ABDOMEN/PELVIS [28S] ^ (#828) GALLIUM SCAN [29S] ^ (#829) PET
==>SCAN [30S] ^ (#830) LUMBAR PUNCTURE [31S] ^ (#831) HEMOGLOBIN/HEMATOCRIT [32S] ^ (#832) WHITE COUNT [33S] ^
==>(#833) PLATELET COUNT [34S] ^ (#834) LACTIC DEHYDROGENASE (LDH) [35S] ^ (#835) LIVER FUNCTION STUDIES (NHL)
==>[36S] ^ (#836) TOTAL PROTEIN/ALBUMIN [37S] ^ (#837) GENE REARRANGEMENTS [38S] ^ (#838) REVIEW OF
==>PATHOLOGY/OTHER INST [39S] ^ (#839) LYMPH NODE BIOPSY [40S] ^ (#840) BONE MARROW BIOPSY [41S] ^ (#841) CSF
==>CYTOLOGY [42S] ^ (#842) OTHER SITE BIOPSY [43S] ^ (#843) SYSTEMIC SYMPTOMS [44S] ^ (#844) CD4 COUNT [45S] ^
==>(#845) HIV VIRAL LOADS [46S] ^
^ONCO(165.5,D0,NHL2)= (#846) SPECIFIC HISTOLOGIC INFO [1S] ^ (#847) CELL TYPE OF LYMPHOMA [2S] ^ (#848) PATIENT STATUS AT
==>DIAGNOSIS [3S] ^ (#849) TYPE OF STAGING SYSTEM (PED) [4P:164.6] ^ (#850) PEDIATRIC STAGE [5F] ^ (#851)
==>STAGED BY (PEDIATRIC STAGE) [6S] ^ (#852) EXTRANODAL SITE 1 [7F] ^ (#853) EXTRANODAL SITE 2 [8F] ^ (#854)
==>EXTRANODAL SITE 3 [9F] ^ (#855) EXTRANODAL SITE W/C-D SURGERY [10F] ^ (#856) EXTRANODAL SITE SURGICAL PROC
==>[11N] ^ (#857) LYMPH NODES ABOVE DIAPHRAGM [12S] ^ (#858) LYMPH NODES BELOW DIAPHRAGM [13S] ^ (#859) BRAIN
==>[14S] ^ (#860) OTHER EXTRANODAL SITE(S) [15S] ^ (#861) TOTAL BODY [16S] ^ (#862) RADIATION/CHEMO SEQUENCE
==>[17N] ^ (#863) PROTOCOL [18S] ^ (#864) SYSTEMIC CHEMOTHERAPY [19S] ^ (#865) SYSTEMIC CHEMOTHERAPY DATE
==>[20D] ^ (#866) SYSTEMIC CHEMOTHERAPY CYCLES [21N] ^ (#867) CHLORAMBUCIL [22S] ^ (#868) CYCLOPHOSPHAMIDE
==>(NHL) [23S] ^ (#869) DOXORUBICIN (NHL) [24S] ^ (#870) FLUDARABINE [25S] ^ (#871) CHOP [26S] ^ (#872) CVP
==>[27S] ^ (#873) COMLA [28S] ^ (#874) MACOP-B [29S] ^ (#875) M-BACOD [30S] ^ (#876) PRO-MACE-Cyta BOM [31S] ^
==>(#877) OTHER SYSTEMIC CHEMO AGENTS [32S] ^ (#878) HIGH DOSE SYSTEMIC CHEMO [33S] ^ (#879) INTRATHECAL
==>CHEMOTHERAPY [34S] ^ (#880) PURPOSE OF INTRATHECAL CHEMO [35S] ^ (#881) INTERFERON (NHL) [36S] ^ (#882)
==>INTERLEUKIN-2 (IL-2) (NHL) [37S] ^ (#883) MONOCLONAL ANTIBODIES [38S] ^ (#884) VACCINE THERAPY [39S] ^
^ONCO(165.5,D0,OVRD)= (#205) OVER-RIDE AGE/SITE/MORPH [1S] ^ (#206) OVER-RIDE SEQNO/DXCONF [2S] ^ (#207) OVER-RIDE SITE/LAT/SEQNO
==>[3S] ^ (#208) OVER-RIDE SURG/DXCONF [4S] ^ (#209) OVER-RIDE SITE/TYPE [5S] ^ (#210) OVER-RIDE HISTOLOGY
==>[6S] ^ (#211) OVER-RIDE REPORT SOURCE [7S] ^ (#212) OVER-RIDE ILL-DEFINE SITE [8S] ^ (#213) OVER-RIDE
==>LEUK,LYMPHOMA [9S] ^ (#214) OVER-RIDE SITE/BEHAVIOR [10S] ^ (#215) OVER-RIDE SITE/EOD/DX DT [11S] ^ (#216)
==>OVER-RIDE SITE/LAT/EOD [12S] ^ (#217) OVER-RIDE SITE/LAT/MORPH [13S] ^ (#218) OVER-RIDE SS/NODESPOS [14S] ^
==>(#219) OVER-RIDE SS/TNM-N [15S] ^ (#220) OVER-RIDE SS/TNM-M [16S] ^ (#221) OVER-RIDE SS/DISMET1 [17S] ^
==>(#222) OVER-RIDE ACSN/CLASS/SEQ [18S] ^ (#223) OVER-RIDE HOSPSEQ/DXCONF [19S] ^ (#224) OVER-RIDE
==>COC-SITE/TYPE [20S] ^ (#225) OVER-RIDE HOSPSEQ/SITE [21S] ^ (#226) OVER-RIDE SITE/TNM-STGGRP [22S] ^
^ONCO(165.5,D0,PM)= (#251) NSLC STAGE 1-3 PATH LN STAGING [1S] ^ (#252) REASON FOR NO LN BIOPSY [2S] ^ (#253) DATE OF SURGERY
==>CONSULT [3D] ^ (#254) INTENT OF SURGERY [4S] ^ (#255) DATE ONCOLOGY CONSULT ORDERED [5D] ^ (#256) DATE
==>ONCOLOGY CONSULT DONE [6D] ^ (#257) CHEMOTHERAPY RECOMMENDED [7S] ^ (#258) INTENT OF CHEMOTHERAPY [8S] ^
==>(#259) TYPE OF CHEMOTHERAPY [9S] ^ (#260) REASON RADIATION STOPPED [10S] ^ (#261) DOC FOR NO PLAT-BASED CHEMO
==>[11S] ^ (#262) MULTIMODALITY RADIATION TYPE [12S] ^ (#270) PREOP OBSTRUCTING LESION [13S] ^ (#264) DATE
==>HOSPICE CONSULT INITIATED [14D] ^ (#265) DATE HOSPICE CONSULT COMPLETED [15D] ^ (#266) DATE HOSPICE CARE
==>INITIATED [16D] ^ (#267) EGFR MUTATION TESTING [17S] ^ (#268) EGFR MUTATION 1 [18S] ^ (#269) EGFR MUTATION 2
==>[19S] ^ (#271) ONCOLOGY REFERRAL [20S] ^ (#272) DATE CHEMOTHERAPY RECOMMENDED [21D] ^ (#273) ANTI-EGFR MoAB
==>THERAPY [22S] ^ (#274) PERIRECTAL LN INVOLVEMENT [23S] ^ (#275) RISK OF RECURRENCE [24S] ^ (#276) ANDROGEN
==>DEPRIVATION THERAPY [25S] ^ (#277) DATE ADT INITIATED [26D] ^ (#278) NON-ADT CHEMOTHERAPY [27S] ^ (#263)
==>REASON HORMONE THERAPY STOPPED [28S] ^
^ONCO(165.5,D0,PRO1)= (#600) CLINICAL DX WITH BONE LESION [1S] ^ (#601) CLINICAL DX BY RECTAL EXAM [2S] ^ (#602) CYTOLOGY [3S] ^
==>(#603) INCIDENTAL FINDING IN TURP [4S] ^ (#604) NEEDLE ASPIRATION BIOPSY [5S] ^ (#605) NEEDLE BIOPSY, NOS
==>[6S] ^ (#606) PERINEAL BIOPSY [7S] ^ (#607) TRANSRECTAL BIOPSY [8S] ^ (#608) TRUS [9S] ^ (#609)
==>TRANSURETHRAL RESECTION [10S] ^ (#610) OTHER METHOD OF DX (PROSTATE) [11S] ^ (#611) BONE MARROW ASPIRATION
==>[12S] ^ (#612) BONE SCAN (PROSTATE) [13S] ^ (#613) BONE X-RAY [14S] ^ (#614) CHEST X-RAY (PROSTATE) [15S] ^
==>(#615) CT SCAN OF PRIMARY SITE [16S] ^ (#616) INTRAVENOUS PYELOGRAM (PRO) [17S] ^ (#617) LIVER SCAN [18S] ^
==>(#618) MRI (PRO) [19S] ^ (#619) PELVIC LYMPH NODE DISSECT (PR) [20S] ^ (#620) PROSTATIC ACID PHOSPHATASE
==>[21S] ^ (#621) PROSTATE SPECIFIC ANTIGEN [22S] ^ (#622) OTHER DIAGNOSTIC INFORMATION [23S] ^ (#623) GLEASON
==>SCORE (CLINICAL) [24F] ^ (#624) RESEARCH PROTOCOL [25S] ^ (#625) RAD THERAPY PLANNED/GIVEN [26S] ^ (#626)
==>INTERSTITIAL RAD PLANNED/GIVEN [27S] ^ (#627) IODINE 125 [28S] ^ (#628) GOLD 198 [29S] ^ (#629) PALLADIUM
==>103 [30S] ^ (#630) IRIDIUM 192 [31S] ^ (#631) OTHER INTERSTITIAL, NOS [32S] ^ (#632) EXTERNAL RAD
==>PLANNED/GIVEN [33S] ^ (#633) PROSTATE REGION ONLY [34S] ^ (#634) PROSTATE AND PELVIC NODES [35S] ^ (#635)
==>PROSTATE & PELVIC PARA-AORTIC [36S] ^ (#636) DISTANT METASTATIC SITES [37S] ^ (#637) OTHER EXTERNAL SITES,
==>NOS [38S] ^ (#638) TOTAL RAD DOSE (PROSTATE) [39S] ^ (#639) TOTAL RAD DOSE (PELVIC NODES) [40S] ^ (#640)
==>TOTAL RAD DOSE (PARA-AORTIC) [41S] ^ (#641) RESEARCH PROTOCOL (RADIATION) [42S] ^ (#642) HORMONE THERAPY
==>PLANNED/GIVEN [43S] ^ (#643) ESTROGENS [44S] ^ (#644) ANTIANDROGENS [45S] ^ (#645) PROGESTATIONAL AGENTS
==>[46S] ^ (#646) LUTEINIZING HORMONES [47S] ^ (#647) ORCHIECTOMY [48S] ^ (#648) OTHER EXOGENOUS HORMONE
==>AGENTS [49S] ^ (#649) BACKACHE (1ST RECURRENCE) [50S] ^ (#650) BONE SCAN (1ST RECURRENCE) [51S] ^ (#651)
==>LETHARGY [52S] ^ (#652) RECTAL EXAM (1ST RECURRENCE) [53S] ^ (#653) TUMOR MARKER (1ST RECURRENCE) [54S] ^
==>(#654) WEIGHT LOSS (1ST RECURRENCE) [55S] ^ (#655) OTHER METHODS (1ST RECURRENCE) [56S] ^ (#656) REASON FOR
==>2ND COURSE [57S] ^
^ONCO(165.5,D0,PRO2)= (#657) FAM HIST OF PROSTATE CA (PR98) [1S] ^ (#658) HEMATURIA (PR98) [2S] ^ (#659) LOWER BACK PAIN (PR98)
==>[3S] ^ (#660) TROUBLE URINATING (PR98) [4S] ^ (#661) CLIN DX W/ BONE LESION (PR98) [5S] ^ (#662) CLIN DX BY
==>RECTAL EXAM (PR98) [6S] ^ (#663) CYTOLOGY (PR98) [7S] ^ (#664) DIGITAL TRANSRECTAL BIO (PR98) [8S] ^ (#665)
==>INCIDENTAL FIND IN TURP (PR98) [9S] ^ (#666) NEEDLE BIOPSY, NOS (PR98) [10S] ^ (#667) PERINEAL BIOPSY
==>(PR98) [11S] ^ (#668) PSA METHOD OF DIAGNOSIS (PR98) [12S] ^ (#669) TRANSRECTAL BIOPSY (PR98) [13S] ^
==>(#670) TRANSURETHRAL RESECTION (PR98) [14S] ^ (#671) BONE MARROW ASPIRATION (PR98) [15S] ^ (#672) BONE SCAN
==>(PR98) [16S] ^ (#673) BONE X-RAY (PR98) [17S] ^ (#674) CHEST X-RAY (PR98) [18S] ^ (#675) CT SCAN OF ABDOMEN
==>(PR98) [19S] ^ (#676) CT SCAN OF PELVIS (PR98) [20S] ^ (#677) INTRAVENOUS PYELOGRAM (PR98) [21S] ^ (#678)
==>MRI (PR98) [22S] ^ (#679) PELVIC LYMPH ND DISSECT (PR98) [23S] ^ (#680) POLYMERASE CHAIN REACT (PR98) [24S]
==>^ (#681) PROSTATIC ACID PHOSPH (PR98) [25S] ^ (#682) PSA DIAGNOSTIC EVAL (PR98) [26S] ^ (#683) ULTRASOUND
==>OF ABDOMEN (PR98) [27S] ^ (#684) PSA [28F] ^ (#685) WATCHFUL WAITING (PR98) [29S] ^ (#686) LENGTH OF STAY
==>(PR98) [30N] ^ (#687) LAPAROSCOPIC (PR98) [31S] ^ (#688) OPEN (PR98) [32S] ^ (#689) PERMANENT RECTAL INJURY
==>(PR98) [33S] ^ (#690) THROMBOEMBOLISM (PR98) [34S] ^ (#691) URETHRAL STRICTURE (PR98) [35S] ^ (#692)
==>RADIATION FACILITY [36S] ^ (#693) ROUTE OF INTERSTITIAL RAD [37S] ^ (#694) TYPE OF RADIATION ADMIN [38S] ^
==>(#695) GASTROINTESTINAL COMPLICATIONS [39S] ^ (#696) GASTROURINARY COMPLICATIONS [40S] ^ (#697) ANORECTAL
==>COMPLICATIONS [41S] ^ (#698) CHRONIC COMPLICATIONS [42S] ^ (#623.1) PREDOMINANT PATTERN (02-40) [43N] ^
==>(#623.2) LESSER PATTERN (02-40) [44N] ^ (#623.3) GLEASON'S SCORE (50-70) [45F] ^ (#623.4) PREDOMINANT
==>PATTERN (50-70) [46N] ^ (#623.5) LESSER PATTERN (50-70) [47N] ^ (#699) URETHRAL/BLADDER COMPLICATIONS [48S]
==>^ (#699.1) DATE OF ORCHIECTOMY [49D] ^ (#96) PSA DATE [50F] ^
^ONCO(165.5,D0,RAD18)= (#5501) PHASE 1 DOSE PER FRACTION [1F] ^ (#5502) PHASE 1 RAD EXT BEAM PLAN TECH [2P:164.81] ^ (#5503)
==>PHASE 1 NUMBER OF FRACTIONS [3F] ^ (#5504) PHASE 1 RAD TREATMENT VOLUME [4P:164.82] ^ (#5505) PHASE 1 RAD
==>TO DRAINING LN [5P:164.83] ^ (#5506) PHASE 1 RAD TREATMENT MODALITY [6P:164.84] ^ (#5507) PHASE 1 TOTAL
==>DOSE [7F] ^ (#5511) PHASE 2 DOSE PER FRACTION [8F] ^ (#5512) PHASE 2 RAD EXT BEAM PLAN TECH [9P:164.81] ^
==>(#5513) PHASE 2 NUMBER OF FRACTIONS [10F] ^ (#5514) PHASE 2 RAD TREATMENT VOLUME [11P:164.82] ^ (#5515)
==>PHASE 2 RAD TO DRAINING LN [12P:164.83] ^ (#5516) PHASE 2 RAD TREATMENT MODALITY [13P:164.84] ^ (#5517)
==>PHASE 2 TOTAL DOSE [14F] ^ (#5521) PHASE 3 DOSE PER FRACTION [15F] ^ (#5522) PHASE 3 RAD EXT BEAM PLAN
==>TECH [16P:164.81] ^ (#5523) PHASE 3 NUMBER OF FRACTIONS [17F] ^ (#5524) PHASE 3 RAD TREATMENT VOLUME
==>[18P:164.82] ^ (#5525) PHASE 3 RAD TO DRAINING LN [19P:164.83] ^ (#5526) PHASE 3 RAD TREATMENT MODALITY
==>[20P:164.84] ^ (#5527) PHASE 3 TOTAL DOSE [21F] ^
^ONCO(165.5,D0,SSD1)= (#3800) SCHEMA ID [1F] ^ (#3801) CHROMOSOME 1P: (LOH) [2S] ^ (#3802) CHROMOSOME 19Q: (LOH) [3S] ^ (#3803)
==>ADENOID CYSTIC BASALOID PTTRN [4F] ^ (#3804) ADENOPATHY [5S] ^ (#3805) AFP POST-ORCHIECTOMY LAB VAL [6F] ^
==>(#3806) AFP POST-ORCHIECTOMY RANGE [7S] ^ (#3807) AFP PRE-ORCHIECTOMY LAB VALUE [8F] ^ (#3808) AFP
==>PRE-ORCHIECTOMY RANGE [9S] ^ (#3809) AFP PRETREATMENT INTERPRET [10S] ^ (#3810) AFP PRETREATMENT LAB VALUE
==>[11F] ^ (#3811) ANEMIA [12S] ^ (#3812) B SYMPTOMS [13S] ^ (#3813) BILIRUBIN PRE TOTAL LAB VALUE [14F] ^
==>(#3814) BILIRUBIN PRETREATMENT UNIT [15S] ^ (#3815) BONE INVASION [16S] ^ (#3816) BRAIN MOLECULAR MARKERS
==>[17P:167.1] ^ (#3817) BRESLOW TUMOR THICKNESS [18F] ^ (#3818) CA-125 PRETREATMENT INTER [19S] ^ (#3819) CEA
==>PRETREATMENT INTER [20S] ^ (#3820) CEA PRETREATMENT LAB VALUE [21F] ^ (#3821) CHROMOSOME 3 STATUS [22S] ^
==>(#3822) CHROMOSOME 8Q STATUS [23S] ^ (#3823) CIRCUMFERENTIAL RESECT MARGIN [24F] ^ (#3824) CREATININE
==>PRETREAT LAB VALUE [25F] ^ (#3825) CREATININE PRETREAT UNIT [26S] ^ (#3826) ER PERCENT POSITIVE [27F] ^
==>(#3827) ER SUMMARY [28S] ^ (#3828) ER ALLRED SCORE [29F] ^ (#3829) ESOPHAGUS EGJ TUMOR EPICENTER [30S] ^
==>(#3830) ENE CLIN (NON-HEAD AND NECK) [31S] ^ (#3831) ENE HEAD AND NECK CLINICAL [32S] ^ (#3832) ENE HEAD
==>AND NECK PATHOLOGICAL [33F] ^ (#3833) ENE PATH (NON-HEAD AND NECK) [34S] ^ (#3834) EXTRAVASCULAR MATRIX
==>PATTERNS [35S] ^
^ONCO(165.5,D0,SSD2)= (#3835) FIBROSIS SCORE [1S] ^ (#3836) FIGO STAGE [2F] ^ (#3837) GESTATIONAL TROPHOBLASTIC [3F] ^ (#3838)
==>GLEASON PATTERNS CLINICAL [4P:167.2] ^ (#3839) GLEASON PATTERNS PATHOLOGICAL [5P:167.2] ^ (#3840) GLEASON
==>SCORE CLINICAL [6S] ^ (#3841) GLEASON SCORE PATHOLOGICAL [7S] ^ (#3842) GLEASON TERTIARY PATTERN [8S] ^ ^
==>^ ^ (#3846) HCG POST-ORCHIECTOMY LAB VALUE [12F] ^ (#3847) HCG POST-ORCHIECTOMY RANGE [13S] ^ (#3848) HCG
==>PRE-ORCHIECTOMY LAB VALUE [14F] ^ (#3849) HCG PRE-ORCHIECTOMY RANGE [15S] ^ (#3850) HER2 IHC SUMMARY [16S]
==>^ (#3851) HER2 ISH DUAL PROBE COPY NUM [17F] ^ (#3852) HER2 ISH DUAL PROBE RATIO [18F] ^ (#3853) HER2 ISH
==>SINGLE PROBE COPY NUM [19F] ^ (#3854) HER2 ISH SUMMARY [20S] ^ (#3855) HER2 OVERALL SUMMARY [21S] ^ (#3856)
==>HERITABLE TRAIT [22S] ^ (#3857) HIGH RISK CYTOGENETICS [23S] ^ (#3858) HIGH RISK HISTOLOGIC FEATURES [24S]
==>^ (#3859) HIV STATUS [25S] ^ (#3860) INR PROTHROMBIN TIME [26F] ^ (#3861) IPSILATERANL ADRENAL GLAND INV
==>[27S] ^ (#3862) JAK2 [28S] ^ (#3863) KI-67 [29F] ^ (#3864) INVASION BEYOND CAPSULE [30S] ^ (#3865) KIT GENE
==>IMMUNOHISTOCHEMISTRY [31S] ^ (#3866) KRAS [32S] ^ (#3867) LDH POST-ORCHIECTOMY RANGE [33S] ^ (#3868) LDH
==>PRE-ORCHIECTOMY RANGE [34S] ^ (#3869) LDH LEVEL [35S] ^ (#3870) LDH UPPER LIMITS OF NORMAL [36F] ^
^ONCO(165.5,D0,SSD3)= (#3871) LN ASSESS METH FEMORAL-INGUIN [1S] ^ (#3872) LN ASSESS METHOD PARA-AORTIC [2S] ^ (#3873) LN
==>ASSESSMENT METHOD PELVIC [3S] ^ (#3874) LN DISTANT ASSESSMENT METHOD [4S] ^ (#3875) LN DISTANT
==>MEDIASTINAL,SCALENE [5S] ^ (#3876) LN HEAD & NECK LEVELS I-III [6S] ^ (#3877) LN HEAD & NECK LEVELS IV-V
==>[7S] ^ (#3878) LN HEAD & NECK LEVELS VI-VII [8S] ^ (#3879) LN HEAD AND NECK OTHER [9S] ^ (#3880) LN
==>ISOLATED TUMOR CELLS (ITC) [10S] ^ (#3881) LN LATERALITY [11S] ^ (#3882) LN POSITIVE AXILLARY LVL I-II
==>[12F] ^ (#3883) LN SIZE [13F] ^ (#3884) LN STATUS FEM-ING,PAR-AOR,PLV [14P:167.3] ^ (#3885) LYMPHOCYTOSIS
==>[15S] ^ (#3886) MAJOR VEIN INVOLVEMENT [16S] ^ (#3887) MEASURED BASAL DIAMETER [17F] ^ (#3888) MEASURED
==>THICKNESS [18F] ^ (#3889) METHYLATION OF MGMT [19S] ^ (#3890) MICROSATELLITE INSTABILITY [20S] ^ (#3891)
==>MICROVASCULAR DENSITY [21F] ^ (#3892) MITOTIC COUNT UVEAL MELANOMA [22F] ^ (#3893) MITOTIC RATE MELANOMA
==>[23F] ^ (#3894) MULTIGENE SIGNATURE METHOD [24S] ^ (#3895) MULTIGENE SIGNATURE RESULTS [25F] ^ (#3896) NCCN
==>IPI [26F] ^ (#3897) NUMBER OF CORES EXAMINED [27F] ^ (#3898) NUMBER OF CORES POSITIVE [28F] ^ (#3899) NUM
==>OF EXAMINED PARA-AORTIC [29F] ^ (#3900) NUM OF EXAMINED PELVIC NODES [30F] ^ (#3901) NUM OF POS PARA-AORTIC
==>NODES [31F] ^ (#3902) NUM OF POSITIVE PELVIC NODES [32F] ^ (#3903) ONCOTYPE DX RECUR SCORE-DCIS [33F] ^
==>(#3904) ONCOTYPE DX REC SCORE-INVASIVE [34F] ^
^ONCO(165.5,D0,SSD4)= (#3905) ONCOTYPE DX RISK LEVEL-DCIS [1S] ^ (#3906) ONCOTYPE DX RISK LEVEL-INVAS [2S] ^ (#3907) ORGANOMEGALY
==>[3S] ^ (#3908) PERCENT NECROSIS PST NEOADJVNT [4F] ^ (#3909) PERINEURAL INVASION 2018 [5S] ^ (#3910)
==>PERIPHERAL BLOOD INVOLV 2018 [6P:167.4] ^ (#3911) PERITONEAL CYTOLOGY [7S] ^ (#3913) PLEURAL EFFUSION [8S]
==>^ (#3914) PR PERCENT POSITIVE [9F] ^ (#3915) PR SUMMARY [10S] ^ (#3916) PR ALLRED SCORE [11F] ^ (#3917)
==>PRIMARY SCLEROSING CHOLANGITIS [12S] ^ (#3918) PROFOUND IMMUNE SUPPRESSION [13S] ^ (#3919) PROSTATE
==>PATHOLOGICAL EXT [14F] ^ (#3920) PSA LAB VALUE [15F] ^ (#3921) RESIDUAL TUM VOL PST CYTO [16P:167.5] ^
==>(#3922) RESPONSE TO NEOADJUVANT THERA [17S] ^ (#3923) S CATEGORY CLINICAL [18S] ^ (#3924) S CATEGORY
==>PATHOLOGICAL [19S] ^ (#3925) SARCOMATOID FEATURES [20F] ^ (#3926) SCHEMA DISCRIMINATOR 1 [21N] ^ (#3927)
==>SCHEMA DISCRIMINATOR 2 [22N] ^ (#3928) SCHEMA DISCRIMINATOR 3 [23N] ^ (#3929) SEPARATE TUMOR NODULES [24S]
==>^ (#3930) SERUM ALBUMIN PRETREAT VALUE [25S] ^ (#3931) SERUM BETA-2 MICROGLOBULIN [26S] ^ (#3932) LDH LAB
==>VALUE [27F] ^ (#3933) THROMBOCYTOPENIA [28S] ^ (#3934) TUMOR DEPOSITS [29F] ^ (#3935) TUMOR GROWTH PATTERNS
==>[30S] ^ (#3936) ULCERATION 2018 [31S] ^ (#3937) VISCERAL PARIETAL PLEURAL INV [32S] ^ (#3700) SEER SSF1-HPV
==>STATUS [33S] ^
^ONCO(165.5,D0,SSD5)= (#3938) ALK REARRANGEMENT [1S] ^ (#3939) EGFR MUTATIONAL ANALYSIS [2S] ^ (#3940) BRAF MUTATIONAL ANALYSIS
==>[3S] ^ (#3941) NRAS MUTATIONAL ANALYSIS [4S] ^ (#3942) CA 19-9 PRETX LAB VALUE [5F] ^ (#3800.1) SCHEMA ID
==>DESCRIPTION [6F] ^ (#3950) MACROSCOPIC EVAL OF MESORECTUM [7S] ^ (#3955) DERIVED RAI STAGE [8S] ^ (#3956)
==>P16 [9S] ^ (#3957) LN STATUS PELVIC [10S] ^ (#3958) LN STATUS PARA-AORTIC [11S] ^ (#3959) LN STATUS
==>FEMORAL-INGUINAL [12S] ^ (#3960) HISTOLOGIC SUBTYPE [13S] ^ (#3961) CLINICAL MARGIN WIDTH [14F] ^
^ONCO(165.5,D0,STS1)= (#500) HISTORY OF SOFT TIS SARC (FAM) [1S] ^ (#501) HISTORY OF ANY CANCER (PT) [2S] ^ (#502) ANGIOGRAM OF
==>PRIMARY [3S] ^ (#503) BONE MARROW ASPIRATE OR BIOPSY [4S] ^ (#504) BONE SCAN (SOFT TIS SARCOMA) [5S] ^
==>(#505) CHEST X-RAY (STS/NHL) [6S] ^ (#506) CT SCAN OF CHEST (STS) [7S] ^ (#507) CT SCAN OF PRIMARY [8S] ^
==>(#508) LIVER FUNCTION STUDIES (STS) [9S] ^ (#509) LYMPHANGIOGRAM [10S] ^ (#510) MRI OF PRIMARY [11S] ^
==>(#511) MRI OF OTHER [12S] ^ (#512) SKELETAL X-RAY [13S] ^ (#513) SONOGRAM [14S] ^ (#514) CYTOGENETICS [15S]
==>^ (#515) ELECTRON MICROSCOPY [16S] ^ (#516) IMMUNOHISTOCHEMISTRY [17S] ^ (#517) IN SITU HYBRIDIZATION [18S]
==>^ (#518) OUTSIDE CONFIRMATION REQUESTED [19S] ^ (#519) SUBSITE [20P:166.3] ^ (#520) TYPE OF ADDITIONAL
==>CODING SYS [21S] ^ (#521) VALUE OF ADDITIONAL CODING SYS [22S] ^ (#522) PATHOLOGIC SIZE OF TUMOR [23N] ^
==>(#523) DEPTH OF TUMOR [24S] ^ (#524) CONSULTATIONS (MED ONCOLOGIST) [25S] ^ (#525) CONSULTATIONS (RAD
==>ONCOLOGIST) [26S] ^ (#528) FINE NEEDLE ASPIRATION [27N] ^ (#529) CORE NEEDLE BIOPSY [28N] ^ (#530)
==>INCISIONAL BIOPSY (STS PCE) [29N] ^ (#531) EXCISIONAL BIOPSY [30N] ^
^ONCO(165.5,D0,STS2)= (#526) TREATING SURGEON [1S] ^ (#527) ASA CLASS [2S] ^ (#532) EXTERNAL BEAM RADIATION [3S] ^ (#533)
==>EXTERNAL BEAM RAD FRACTIONS [4N] ^ (#534) EXTERNAL BEAM RADIATION ENERGY [5N] ^ (#535) INTRAOPERATIVE
==>RADIATION [6S] ^ (#536) INTRAOPERATIVE RADIATION DOSE [7N] ^ (#537) INTRAOPERATIVE RADIATION ENER [8N] ^
==>(#538) BRACHYTHERAPY [9S] ^ (#539) BRACHYTHERAPY DAYS [10N] ^ (#540) BRACHYTHERAPY RADIATION DOSE [11N] ^
==>(#541) DATE BRACHYTHERAPY STARTED [12D] ^ (#542) DATE BRACHYTHERAPY ENDED [13D] ^ (#543) CYTOXAN [14S] ^
==>(#544) DTIC [15S] ^ (#545) DOXORUBICIN (STS) [16S] ^ (#546) ETOPOSIDE [17S] ^ (#547) CISPLATIN METHOD OF
==>DELIVERY [18S] ^ (#548) CYTOXAN METHOD OF DELIVERY [19S] ^ (#549) DTIC METHOD OF DELIVERY [20S] ^ (#550)
==>DOXORUBICIN METHOD OF DELIVERY [21S] ^ (#551) ETOPOSIDE METHOD OF DELIVERY [22S] ^ (#552) IFOSFAMIDE METHOD
==>OF DELIVERY [23S] ^ (#553) CISPLATIN LOCATION [24S] ^ (#554) CYTOXAN LOCATION [25S] ^ (#555) DTIC LOCATION
==>[26S] ^ (#556) DOXORUBICIN LOCATION [27S] ^ (#557) ETOPOSIDE LOCATION [28S] ^ (#558) IFOSFAMIDE LOCATION
==>[29S] ^ (#559) COLONY STIMULATING FACTORS [30S] ^ (#560) PROTOCOL PARTICIPATION [31S] ^ (#561) OTHER
==>PROTOCOL [32S] ^ (#562) REFERRED TO REHAB SERVICES [33S] ^ (#563) PHYSICAL THERAPY/REHABILTATION [34S] ^
==>(#564) TRANSFERRED TO REHABILITATION [35S] ^ (#565) NUMBER OF HOSPITALIZATIONS [36N] ^ (#566) TOTAL LENGTH
==>OF STAYS [37N] ^ (#567) DATE EXT BEAM RAD STARTED [38D] ^
^ONCO(165.5,D0,THY1)= (#400) HISTORY OF THYROID CA (FAM) [1S] ^ (#401) HISTORY OF LYMPHOMA (PT) [2S] ^ (#402) HISTORY OF
==>CHILDHOOD MALIG [3S] ^ (#403) PRIOR EXPOSURE TO RADIATION [4S] ^ (#404) HISTORY OF GOITER (PT) [5S] ^
==>(#405) HISTORY OF GOITER (FAM) [6S] ^ (#406) HISTORY OF GRAVES DISEASE (PT) [7S] ^ (#407) HISTORY OF
==>THYROIDITIS (PT) [8S] ^ (#408) DYSPHAGIA [9S] ^ (#409) HOARSENESS OR VOICE CHANGE [10S] ^ (#410) NECK NODAL
==>MASS [11S] ^ (#411) PAIN, BONE [12S] ^ (#412) PAIN, NECK [13S] ^ (#413) PATHOLOGIC FRACTURE [14S] ^ (#414)
==>STRIDOR/DIFFICULTY BREATHING [15S] ^ (#415) THYROID MASS [16S] ^ (#416) WEIGHT LOSS [17S] ^ (#417) OTHER
==>SIGNS/SYMPTOMS [18S] ^ (#418) BONE SCAN (THYROID) [19S] ^ (#419) CHEST X-RAY (THYROID) [20S] ^ (#420) CT
==>SCAN OF NECK (THYROID) [21S] ^ (#421) CT SCAN OF CHEST [22S] ^ (#422) INCISIONAL BIOPSY OF THYROID [23S] ^
==>(#423) LARYNGOSCOPY [24S] ^ (#424) NECK X-RAY (AP & LATERAL) [25S] ^ (#425) NEEDLE ASPIRATION OF NECK NODE
==>[26S] ^ (#426) NEEDLE ASPIRATION OF THYROID [27S] ^ (#427) MRI OF NECK [28S] ^ (#428) THYROID SCAN [29S] ^
==>(#429) ULTRASOUND OF THYROID [30S] ^ (#430) OTHER DIAGNOSTIC/SURGICAL TEST [31S] ^ (#431) BLOOD VESSEL
==>INVASION [32S] ^ (#432) EXTRA-THYROIDAL EXTENSION [33S] ^ (#433) MULTIFOCAL [34S] ^ (#434) LOCATION OF
==>POSITIVE NODES [35S] ^ (#435) DATE MOST DEFINITIVE SURG DIS [36D] ^ (#436) AIRWAY PROBLEM [37S] ^ (#437)
==>BLEEDING/HEMATOMA [38S] ^ (#438) HYPOCALCEMIA [39S] ^ (#439) RECURRENT NERVE INJURY [40S] ^ (#440) WOUND
==>INFECTION [41S] ^ (#441) POSTOPERATIVE DEATH [42S] ^ (#442) REGIONAL DOSE: cGy [43N] ^ (#443) BOOST DOSE:
==>cGy [44N] ^ (#444) INITIAL DOSE OF RADIOIODINE [45N] ^ (#445) SECOND DOSE OF RADIOIODINE [46N] ^ (#446)
==>ADJUVANT CHEMOTHERAPY (THY) [47S] ^
^ONCO(165.5,D0,TS,0)=^165.573DA^^ (#73) TUMOR STATUS
^ONCO(165.5,D0,TS,D1,0)= (#.01) TUMOR STATUS DATE [1D] ^ (#.02) CANCER STATUS [2P:164.42] ^ (#.03) DATE OF LAST CANCER STATUS
==>[3D] ^ (#.04) DATE OF LAST CANCER STATUS FLG [4S] ^
INPUT TEMPLATE(S):
^DIE(1263)= ONCO ABSTRACT-I
^DIE(1262)= ONCO RECURRENCE FOLLOWUP
^DIE(1261)= ONCO UTL CORRECT DATA
PRINT TEMPLATE(S):
^DIPT(1295)= ONC EXTRACT REPORT
^DIPT(838)= ONCO ABSTRACT NOT-COMPLETE
^DIPT(830)= ONCO ACCREG-ACOS80
^DIPT(831)= ONCO ACCREG-EOVA132
^DIPT(832)= ONCO ACCREG-SITE/GP80
^DIPT(855)= ONCO AJCC SUMMARY STAGE GPS
^DIPT(833)= ONCO ANNUAL ACCREG80
^DIPT(834)= ONCO ANNUAL ACCREG80-HDR
^DIPT(854)= ONCO ANNUAL CLASS/PATIENT
^DIPT(853)= ONCO ANNUAL CLASS/PATIENT-HDR
^DIPT(866)= ONCO ANNUAL HIST/SITE/ICDO
^DIPT(864)= ONCO ANNUAL ICDO/STAGE/TX
^DIPT(840)= ONCO ANNUAL PATIENT INDX
^DIPT(841)= ONCO ANNUAL PATIENT INDX-HDR
^DIPT(868)= ONCO ANNUAL PATIENT INFO
^DIPT(867)= ONCO ANNUAL PATIENT INFO-HDR
^DIPT(819)= ONCO ANNUAL SITE/GP
^DIPT(818)= ONCO ANNUAL SITE/GP-HDR
^DIPT(856)= ONCO ANNUAL SITE/ICDT/ICDM
^DIPT(871)= ONCO ANNUAL SITE/STAGE/TX
^DIPT(870)= ONCO ANNUAL SITE/STAGE/TX-HDR
^DIPT(869)= ONCO ANNUAL SITE/STG/TX
^DIPT(857)= ONCO ANNUAL TREATMENT
^DIPT(858)= ONCO ICDO PATIENT LIST
^DIPT(823)= ONCO ICDO-SITE132
^DIPT(822)= ONCO ICDO-SITE132-HDR
^DIPT(821)= ONCO ICDO-SITE80
^DIPT(820)= ONCO ICDO-SITE80-HDR
^DIPT(1277)= ONCO PATIENT INDX-ACOS
^DIPT(879)= ONCO PRIMARY EXTENT CODE AUDIT
^DIPT(865)= ONCO PRIMARY INFORMATION132
^DIPT(880)= ONCO PRIMARY SURGERY AUDIT
^DIPT(836)= ONCO SITE/GP80
^DIPT(837)= ONCO SITE/GP80-HDR
^DIPT(824)= ONCO SITE80
^DIPT(825)= ONCO SITE80-HEADER
^DIPT(859)= ONCO TREATMENT
^DIPT(826)= ONCO XABSTRACT RECORD Compiled: ^ONCOXU
^DIPT(835)= ONCO XADMISSION Compiled: ^ONCOXS1
^DIPT(872)= ONCO XINCIDENCE RPRT Compiled: ^ONCOXNC
^DIPT(874)= ONCOW1 Compiled: ^ONCOW1
^DIPT(842)= ONCOX1 Compiled: ^ONCOW
^DIPT(851)= ONCOX10 Compiled: ^ONCOX10
^DIPT(852)= ONCOX11 Previously Compiled: ONCOX11
^DIPT(843)= ONCOX2 Compiled: ^ONCOX2
^DIPT(844)= ONCOX3 Compiled: ^ONCOX3
^DIPT(845)= ONCOX4 Compiled: ^ONCOX4
^DIPT(846)= ONCOX5 Compiled: ^ONCOX5
^DIPT(847)= ONCOX6 Compiled: ^ONCOX6
^DIPT(848)= ONCOX7 Compiled: ^ONCOX7
^DIPT(849)= ONCOX8 Compiled: ^ONCOX8
^DIPT(850)= ONCOX9 Compiled: ^ONCOX9
^DIPT(873)= ONCOX99
^DIPT(827)= ONCOXA1 Compiled: ^ONCOXA1
^DIPT(828)= ONCOXA2 Compiled: ^ONCOXA2
^DIPT(829)= ONCOXA3 Compiled: ^ONCOXA3
^DIPT(839)= ONCOXA4 Compiled: ^ONCOXA4
^DIPT(817)= ONCOY49 Compiled: ^ONCOY49
^DIPT(860)= ONCOY50 Compiled: ^ONCOY50
^DIPT(861)= ONCOY51 Compiled: ^ONCOY51
^DIPT(862)= ONCOY52 Compiled: ^ONCOY52
^DIPT(863)= ONCOY53 Compiled: ^ONCOY53
^DIPT(812)= ONCOY54 Compiled: ^ONCOY54
^DIPT(813)= ONCOY55 Compiled: ^ONCOY55
^DIPT(814)= ONCOY56 Compiled: ^ONCOY56
^DIPT(815)= ONCOY57 Compiled: ^ONCOY57
^DIPT(816)= ONCOY58 Compiled: ^ONCOY58
^DIPT(1431)= ONCQA
^DIPT(1432)= ONCQA1
^DIPT(1524)= ONCQA2
^DIPT(1525)= ONCQA3
SORT TEMPLATE(S):
^DIBT(489)= ONCO ABSTINCOM-TERMDIG
^DIBT(490)= ONCO ABSTRACT DATE/COMPLETE
^DIBT(417)= ONCO ABSTRACT NOT-COMPLETE
^DIBT(909)= ONCO ABSTRACT NOT-COMPLETE 1
^DIBT(446)= ONCO ABSTRACT RECORD
^DIBT(413)= ONCO ACCREG-ACOS80
^DIBT(415)= ONCO ACCREG-EOVA132
^DIBT(414)= ONCO ACCREG-SITE/GP80
^DIBT(465)= ONCO ANN/ANAL/STA/SITE/DX AGE
^DIBT(419)= ONCO ANNUAL ACCREG80
^DIBT(442)= ONCO ANNUAL ACOSACCREG80
^DIBT(441)= ONCO ANNUAL ANALYTIC
^DIBT(418)= ONCO ANNUAL CLASS/PATIENT
^DIBT(445)= ONCO ANNUAL CLASS/SITE
^DIBT(450)= ONCO ANNUAL HIST/SITE/ICDO
^DIBT(449)= ONCO ANNUAL ICDO/STAGE/TX
^DIBT(420)= ONCO ANNUAL PATIENT INDX
^DIBT(438)= ONCO ANNUAL SITE/GP
^DIBT(423)= ONCO ANNUAL SITE/ICDT/ICDM
^DIBT(447)= ONCO ANNUAL SITE/STAGE/TX
^DIBT(444)= ONCO ICDO-SITE
^DIBT(440)= ONCO ICDO-SITE132
^DIBT(439)= ONCO ICDO-SITE80
^DIBT(493)= ONCO PCE ANNUAL REPORT
^DIBT(416)= ONCO SITE/GP80
^DIBT(443)= ONCO STAGE/SITE
^DIBT(448)= ONCOS ANAL/STAGE 0
^DIBT(451)= ONCOS ANAL/STAGE I
^DIBT(452)= ONCOS ANAL/STAGE II
^DIBT(453)= ONCOS ANAL/STAGE III
^DIBT(454)= ONCOS ANAL/STAGE IV
^DIBT(499)= ONCOS ANAL/STAGE NA
^DIBT(455)= ONCOS ANAL/STAGE U
^DIBT(457)= ONCOS ANALYTIC
^DIBT(427)= ONCOS ANALYTIC-140
^DIBT(425)= ONCOS ANALYTIC-153
^DIBT(426)= ONCOS ANALYTIC-154
^DIBT(421)= ONCOS ANALYTIC-160
^DIBT(424)= ONCOS ANALYTIC-161
^DIBT(422)= ONCOS ANALYTIC-162
^DIBT(428)= ONCOS ANALYTIC-193
^DIBT(429)= ONCOS ANALYTIC-196
^DIBT(459)= ONCOS ANALYTIC_NON
^DIBT(436)= ONCOS ANNUAL ANAL/STAGE 0
^DIBT(432)= ONCOS ANNUAL ANAL/STAGE I
^DIBT(433)= ONCOS ANNUAL ANAL/STAGE II
^DIBT(434)= ONCOS ANNUAL ANAL/STAGE III
^DIBT(435)= ONCOS ANNUAL ANAL/STAGE IV
^DIBT(500)= ONCOS ANNUAL ANAL/STAGE NA
^DIBT(437)= ONCOS ANNUAL ANAL/STAGE U
^DIBT(462)= ONCOS ANNUAL-ALLCASES
^DIBT(456)= ONCOS ANNUAL-ANALYTIC
^DIBT(458)= ONCOS ANNUAL-NON ANAL
^DIBT(487)= ONCOS ANNUAL/ANAL-90
^DIBT(479)= ONCOS KAPOSI
^DIBT(480)= ONCOS LARYNX/AN/90
^DIBT(494)= ONCOS LUNG/NON-SMALL CELL
^DIBT(491)= ONCOS MEMPHIS LUNG
^DIBT(430)= ONCOS NON-ANALYTIC
^DIBT(460)= ONCOS RANGE-ALLCASES
^DIBT(431)= ONCOS RANGE-ANALYTIC
^DIBT(461)= ONCOS RANGE-NON ANAL
^DIBT(482)= ONCOS SITE=BLADDER
^DIBT(470)= ONCOS SITE=BRAIN
^DIBT(492)= ONCOS SITE=BREAST
^DIBT(468)= ONCOS SITE=COLON
^DIBT(483)= ONCOS SITE=ESOHAGUS
^DIBT(485)= ONCOS SITE=HODGKIN'S
^DIBT(471)= ONCOS SITE=HODGKINS
^DIBT(473)= ONCOS SITE=LARYNX
^DIBT(469)= ONCOS SITE=LIP
^DIBT(488)= ONCOS SITE=LIVER
^DIBT(467)= ONCOS SITE=LUNG
^DIBT(474)= ONCOS SITE=LYMPH NODES
^DIBT(472)= ONCOS SITE=NON-HODGKINS
^DIBT(486)= ONCOS SITE=NON-HODGKINS'S
^DIBT(484)= ONCOS SITE=PHARYNX
^DIBT(466)= ONCOS SITE=PROSTATE
^DIBT(481)= ONCOS SITE=TESTIS
^DIBT(463)= ONCOS TOTAL-ANAL
^DIBT(464)= ONCOS TOTAL-NON
^DIBT(476)= ONCOS TX-CHEMO
^DIBT(478)= ONCOS TX-HORMONE
^DIBT(477)= ONCOS TX-RADIATION
^DIBT(475)= ONCOS TX-SURGERY
^DIBT(498)= ONCOZ LUNG SURVIVAL
FORM(S)/BLOCK(S):